[cover page generated for ClinicalTrials.gov only. This page was not part of the IRB approved document  
which follows] Identifiers:  [STUDY_ID_REMOVED]  
Unique Protocol ID:  16-301 
Brief Title:  Pembrolizumab in Metastatic Anal Cancer  
Full Title:  A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer  
 
     
 
      
 
     
 
 Date document downloaded from OncPro portal: 2.22.2023 Document Date: Protocol Version: 07.29.2021  
1DF/HCC Protocol #:  16-301
TITLE:  A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer
Coordinating Center: Dana-Farber Cancer Institute
Principal Investigator (PI): James Cleary MD, PhD, Dana-Farber Cancer Institute
617-632-6073
jcleary@partners.org
Co-Investigators:
Jessica Zerillo, MD, Beth Israel Deaconess Medical Center
Jeffrey Clark, MD, Massachusetts General Hospital
Andrew Coveler, MD, Seattle Cancer Care Alliance
Statistician: Lead Site Study Coordinator: 
Hui Zheng, PhD Katherine Metayer
Massachusetts General Hospital Dana-Farber Cancer Institute
hzheng1@partners.org KatherineA_Metayer@dfci.harvard.edu
Responsible Research Nurses:  
Christopher Graham, RN, BSN Victoria Germon, RN, BSN, OCN
Dana-Farber Cancer Institute Dana-Farber Cancer Institute
Christopher_Graham@dfci.harvard.edu Victoria_Germon@dfci.harvard.edu
Agent(s): Pembrolizumab (MK-3475) (NSC 776864)
IND #: 130680
IND Sponsor:  James Cleary, MD/PhD
Protocol Version Date: Version 5.2 / 29-JUL-2021
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
2SCHEMA
Eligibility Screening 
and Pretreatment 
BiopsyPembrolizumab 
every 3 weeks
(one cycle = 3 
weeks)Continue 
Treatment until 
ProgressionOptional Biopsy 
for Patients with 
Acquired 
ResistanceRegistration
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
3TABLE OF CONTENTS
1. TRIAL SUMMARY ............................................................................................................6
2. TRIAL DESIGN ..................................................................................................................6
2.1 Trial Design .............................................................................................................6
3. OBJECTIVE(S) & HYPOTHESIS(ES) ..............................................................................6
3.1 Primary Objective(s) & Hypothesis(es)...................................................................6
3.2 Secondary Objectives & Hypotheses.......................................................................7
3.3 Exploratory Objective..............................................................................................7
4. BACKGROUND & RATIONALE .....................................................................................7
4.1 Background..............................................................................................................7
4.2 Pharmaceutical and Therapeutic Background .........................................................8
4.3 Rationale ..................................................................................................................9
5. PARTICIPANT SELECTION...........................................................................................11
5.1 Eligibility Criteria ..................................................................................................11
5.2 Subject Exclusion Criteria .....................................................................................12
5.3 Inclusion of Women and Minorities ......................................................................14
6. REGISTRATION PROCEDURES ...................................................................................14
6.1 General Guidelines for DF/HCC and DF/PCC Institutions...................................14
6.2 Registration Process for DF/HCC and DF/PCC Institutions .................................15
6.3 General Guidelines for Other Investigative Sites ..................................................15
6.4 Registration Process for Other Investigative Sites.................................................15
7. TREATMENT PLAN........................................................................................................15
7.1 Trial Treatment ......................................................................................................15
7.2 Pre-Treatment Criteria ...........................................................................................16
7.3 Concomitant Medications/Vaccinations (allowed & prohibited) ..........................16
7.4 Diet/Activity/Other Considerations .......................................................................17
7.5 Criteria for Taking a Participant Off Protocol Therapy.........................................18
7.6 Clinical Criteria for Early Trial Termination.........................................................20
7.7 Duration of Follow Up...........................................................................................20
7.8 Criteria for Taking a Participant Off Study ...........................................................20
8. DOSING DELAYS/DOSE MODIFICATIONS ...............................................................21
8.1 Dose Modification .................................................................................................21
8.2 Rescue Medications & Supportive Care................................................................22
9. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................26
9.1 Expedited Adverse Event Reporting......................................................................26
9.2 Expedited Reporting to the Food and Drug Administration (FDA) ......................26
9.3 Expedited Reporting to Hospital Risk Management .............................................27
9.4 Routine Adverse Event Reporting .........................................................................27
9.5 Definition of an Adverse Event and Reporting of Adverse Events to 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
4Merck .....................................................................................................................27
9.6 Definition of an Overdose for This Protocol and Reporting of Overdose to 
the Sponsor and to Merck ......................................................................................28
9.7 Reporting of Pregnancy and Lactation to the Sponsor and to Merck....................28
9.8 Immediate Reporting of Adverse Events to the Sponsor and to Merck ................28
10. PHARMACEUTICAL  INFORMATION.........................................................................32
10.1 Investigational Product ..........................................................................................32
10.2 Packaging and Labeling Information.....................................................................33
10.3 Clinical Supplies Disclosure..................................................................................33
10.4 Storage and Handling Requirements .....................................................................33
10.5 Ordering .................................................................................................................33
10.6 Returns and Reconciliation....................................................................................33
The investigator is responsible for keeping accurate records of the clinical 
supplies received from Merck or designee, the amount dispensed to the 
subjects and the amount remaining at the conclusion of the trial..........................33
Upon completion or termination of the study, all unused and/or partially used 
investigational product will be destroyed at the site per institutional policy. 
It is the Investigator’s responsibility to arrange for disposal of all 
empty containers, provided that procedures for proper disposal have been 
established according to applicable federal, state, local and institutional 
guidelines and procedures, and provided that appropriate records of 
disposal are kept.....................................................................................................33
11. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ........................................33
11.1 Biomarker Studies..................................................................................................33
12. STUDY CALENDAR and Visit requirements..................................................................39
12.1 Survival Follow-up ................................................................................................40
13. MEASUREMENT OF EFFECT .......................................................................................41
13.1 Antitumor Effect – Solid Tumors ..........................................................................41
14. DATA REPORTING / REGULATORY REQUIREMENTS...........................................48
14.1 Data Reporting.......................................................................................................48
14.2 Data Safety Monitoring..........................................................................................49
14.3 Multicenter Guidelines...........................................................................................49
15. STATISTICAL CONSIDERATIONS...............................................................................49
15.1 Study Design/Endpoints ........................................................................................49
16. PUBLICATION PLAN .....................................................................................................51
REFERENCES ..............................................................................................................................52
APPENDIX A PERFORMANCE STATUS CRITERIA ..................................................54
APPENDIX B Events of clinical interest...........................................................................55
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
51. OVERVIEW ..............................................................................................................................55
2. ECI REPORTING GUIDELINES.............................................................................................57
3. ECI CATEGORIES AND TERMS ...........................................................................................57
3.1 Pneumonitis .................................................................................................................58
3.2 Colitis...........................................................................................................................59
3.3 Endocrine .....................................................................................................................60
Type 1 diabetes mellitus (if new onset) and ≥ Grade 3 Hyperglycemia............................62
3.4 Hematologic.................................................................................................................62
3.5 Hepatic .........................................................................................................................63
3.6 Neurologic....................................................................................................................65
3.7 Ocular...........................................................................................................................65
3.8 Renal ............................................................................................................................66
3.9 Skin ..............................................................................................................................67
3.10 Other ..........................................................................................................................69
3.11 Infusion Reactions .....................................................................................................70
3.12 Follow-up to Resolution ............................................................................................72
4. REFERENCES ..........................................................................................................................73
5. Events of Clinical Interest (ECI) – Reference Table .................................................................74
APPENDIX C – Past Medical History Related to Dermatologic Event........................................75
APPENDIX D – Presentation of the Dermatologic Event.............................................................76
APPENDIX E – Focused Skin Examination .................................................................................78
APPENDIX F – DF/HCC Multi-center data and safety monitoring plan .....................................79
16.1 3.1 DRUG PRODUCT ..........................................................................................80
16.2 3.2 STABILITY AND HANDLING OF DRUG PRODUCT...............................80
16.3 3.3 DOSE CALCULATION..................................................................................82
16.4 4.4 PREPARATION OF INFUSION SOLUTION ...............................................82
16.5 3.5 ADMINISTRATION.......................................................................................84
16.6 3.6 RETURN AND DISCARDING OF PEMBROLIZUMAB (MK-3475) 
VIALS....................................................................................................................85
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
61. TRIAL SUMMARY
Abbreviated Title Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer
Trial Phase Phase 2
Clinical Indication Anal cancer
Trial Type Open label phase 2 study
Type of control Historical control
Route of administration Intravenous
Trial Blinding Non-blinded
Treatment Groups One
Number of trial subjects 32
Estimated enrollment period 18 months
Estimated duration of trial 36 months
Duration of Participation 36 months
2. TRIAL DESIGN
2.1 Trial Design
This is a multicenter, open label, single arm phase 2 clinical trial of pembrolizumab in metastatic 
anal cancer.  Metastatic anal cancer patients who have progressed on a prior regimen of platinum 
and 5-FU-based chemotherapy are eligible to participate. All 32 patients enrolled on the study will 
receive pembrolizumab administered every three weeks.
Patients will continue on the trial until they suffer intolerable toxicity or are found to have disease 
progression by RECIST criteria (RECIST version 1.1). Given the possibility of a delayed tumor 
response, patients will be allowed to continue on the trial until there is disease progression on two 
successive imaging studies (Wolchok et al., 2009). Toxicity will be graded according to CTCAE 
4.0. Optional post-treatment biopsies will be performed on patients who initially respond to 
pembrolizumab and then develop acquired resistance.
3. OBJECTIVE(S) & HYPOTHESIS(ES)
3.1 Primary Objective(s) & Hypothesis(es)
(1)Objective: 
Evaluate the response rate, by RECIST 1.1, of pembrolizumab in metastatic anal cancer 
patients.
Hypothesis:  
Pembrolizumab will show a response rate of ≥20% in metastatic anal cancer patients
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
73.2 Secondary Objectives & Hypotheses
(1)Objective :
Evaluate the response rate, by RECIST 1.1, of pembrolizumab in metastatic anal cancer 
patients who are PD-L1 positive. 
Hypothesis:  
Pembrolizumab will have anti-cancer activity in PD-L1 positive metastatic anal cancer.
(2) Objective :
Evaluate the durability of pembrolizumab response in PD-L1 positive metastatic anal cancer 
patients by measuring median overall survival and median progression free survival
Hypothesis:
The response to pembrolizumab in metastatic anal cancer will be durable and will 
significantly increase progression free survival.
(3)Objective
Evaluate the safety and tolerability of pembrolizumab administered every three weeks, in 
metastatic anal cancer.
Hypothesis:
Pembrolizumab every 3 weeks will be well tolerated in the metastatic anal cancer patient 
population.
3.3 Exploratory Objective
(1) Objective: 
Evaluate relationship between response rate, by RECIST 1.1, and potential predictive 
biomarkers. 
Hypothesis:
Molecular analysis of pre-treatment tumor biopsy samples as well as serially collected 
PBMCs and plasma samples will enable us to identify biomarkers predictive of 
pembrolizumab response.
4. BACKGROUND & RATIONALE
4.1 Background
Metastatic anal cancer is an incurable malignancy that has limited therapeutic options. NCCN 
guidelines recommend cisplatin and 5-FU as first line therapy based several cases series 
demonstrating the activity of this regimen (Dewdney and Rao, 2012; Faivre et al., 1999). Beyond 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
8first line cisplatin and 5-FU, NCCN guidelines make no recommendations for subsequent lines of 
therapy as “no other regimens have shown to be effective (Benson et al., 2012).”
Recently, immunotherapies directed against the immune checkpoint molecules CTLA-4 and PD-
1 have shown very great promise in the treatment of metastatic melanoma. Ipilimumab, a fully 
humanized antibody directed against CTLA-4, was FDA approved for the treatment of melanoma 
after two randomized phase 3 clinical trials showed a significant survival benefit (Hodi et al., 2010; 
Robert et al., 2011). Monoclonal antibodies directed against PD-1, pembrolizumab and nivolumab, 
have also shown promising results in metastatic melanoma, non-small cell lung cancer, and renal 
cancer (Brahmer et al., 2010; Hamid et al., 2013; Robert et al.; Topalian et al., 2014). Importantly, 
in melanoma the majority of responses to both CTLA-4 and PD-1 directed-therapies appear to be 
durable and last for greater than one year (Ott et al., 2013; Topalian et al., 2014). Pembrolizumab 
was granted FDA approval in  2014 on the basis of a phase 1 clinical trial expansion cohort of 173 
patients with refractory metastatic melanoma (Robert et al.). Refractory melanoma patients 
receiving pembrolizumab had an overall response rate of 26% and 88% of the responding patients 
were still benefitting from the drug after 6 months (Robert et al.). Pembrolizumab was generally 
well tolerated and drug-related grade 3 and 4 toxicity occurred in only 13% of patients (Robert et 
al.).
A large, multicenter phase 1 clinical trial testing pembrolizumab in several disease cohorts is 
currently underway (MK-3475-028, [STUDY_ID_REMOVED]). This trial is molecularly prescreening 
patients for PD-L1 positivity. Preliminary data generated by this prescreening effort showed that 
86% of 31 metastatic anal cancers patients were PD-L1 positive. Interestingly, other HPV 
associated tumors (head/neck and cervical cancer) also had a very high rate of PD-L1 positivity. 
The Dana-Farber experience on this trial (MK-3475-028, [STUDY_ID_REMOVED]) suggests that 
pembrolizumab is active in patients with refractory metastatic anal cancer. The first anal cancer 
patient treated at Dana-Farber has had a 59% decrease in her tumor burden after eight cycles of 
pembrolizumab. 
This is a multicenter, open label, single arm phase 2 clinical trial of pembrolizumab in metastatic 
anal cancer. If this trial demonstrates activity it would open up a new therapeutic opportunity in a 
disease with very limited options. It is our hope that a demonstration of clinical activity would 
catalyze the inclusion of pembrolizumab in the NCCN guidelines allowing it to become a standard 
therapy for this cancer.
4.2 Pharmaceutical and Therapeutic Background
The importance of intact immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades.  Accumulating evidence shows a correlation between 
tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various 
malignancies.  In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells / 
FoxP3+ regulatory T-cells seems to correlate with improved prognosis and long-term survival in 
many solid tumors.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
9The PD-1 receptor-ligand interaction is a major pathway hijacked by tumors to suppress immune 
control.  The normal function of PD-1, expressed on the cell surface of activated T-cells under 
healthy conditions, is to down-modulate unwanted or excessive immune responses, including 
autoimmune reactions.  PD-1 (encoded by the gene Pdcd1) is an Ig superfamily member related to 
CD28 and CTLA-4 which has been shown to negatively regulate antigen receptor signaling upon 
engagement of its ligands (PD-L1 and/or PD-L2).  The structure of murine PD-1 has been resolved.  
PD-1 and family members are type I transmembrane glycoproteins containing an Ig Variable-type 
(V-type) domain responsible for ligand binding and a cytoplasmic tail which is responsible for the 
binding of signaling molecules.  The cytoplasmic tail of PD-1 contains 2 tyrosine-based signaling 
motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor 
tyrosine-based switch motif (ITSM).  Following T-cell stimulation, PD-1 recruits the tyrosine 
phosphatases SHP-1 and SHP-2 to the ITSM motif within its cytoplasmic tail, leading to the 
dephosphorylation of effector molecules such as CD3ζ, PKCθ and ZAP70 which are involved in 
the CD3 T-cell signaling cascade.  The mechanism by which PD-1 down modulates T-cell 
responses is similar to, but distinct from that of CTLA-4 as both molecules regulate an overlapping 
set of signaling proteins.  PD-1 was shown to be expressed on activated lymphocytes including 
peripheral CD4+ and CD8+ T-cells, B-cells, T regs and Natural Killer cells.  Expression has also 
been shown during thymic development on CD4-CD8- (double negative) T-cells as well as subsets 
of macrophages and dendritic cells.  The ligands for PD-1 (PD-L1 and PD-L2) are constitutively 
expressed or can be induced in a variety of cell types, including non-hematopoietic tissues as well 
as in various tumors .  Both ligands are type I transmembrane receptors containing both IgV- and 
IgC-like domains in the extracellular region and contain short cytoplasmic regions with no known 
signaling motifs.  Binding of either PD-1 ligand to PD-1 inhibits T-cell activation triggered through 
the T-cell receptor.  PD-L1 is expressed at low levels on various non-hematopoietic tissues, most 
notably on vascular endothelium, whereas PD-L2 protein is only detectably expressed on antigen-
presenting cells found in lymphoid tissue or chronic inflammatory environments.  PD-L2 is 
thought to control immune T-cell activation in lymphoid organs, whereas PD-L1 serves to dampen 
unwarranted T-cell function in peripheral tissues.  Although healthy organs express little (if any) 
PD-L1, a variety of cancers were demonstrated to express abundant levels of this T-cell inhibitor.  
PD-1 has been suggested to regulate tumor-specific T-cell expansion in subjects with melanoma 
(MEL).  This suggests that the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion 
and should be considered as an attractive target for therapeutic intervention.
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the 
IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-
L1 and PD-L2.  KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for 
the treatment of patients with unresectable or metastatic melanoma and disease progression 
following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
4.3 Rationale
4.3.1 Rationale for the Trial and Selected Subject Population
Metastatic squamous cell carcinoma of the anus is a malignancy with extremely limited treatment 
options. An ongoing phase 1 trial has shown that pembrolizumab has activity in some metastatic 
anal cancer patients. This trial is being performed to further characterize pembrolizumab’s activity 
in this disease population. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
10In July 2017, the trial’s eligibility criteria were amended. The requirement that patients receive 
one line of chemotherapy prior to entering the trial was eliminated. The rationale for this is that a 
phase 2 clinical trial testing nivolumab in refractory metastatic anal cancer showed an impressive 
24% radiological response rate (Morris et al., 2017). The encouraging results from the nivolumab 
trial has made recruitment to this trial challenging because many patients are receiving off-label 
PD1 directed therapy in the first line of treatment.
4.3.2 Rationale for Dose Selection/Regimen/Modification 
An open-label Phase I trial (Protocol 001) is being conducted to evaluate the safety and clinical 
activity of single agent pembrolizumab.  The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks (Q2W) in subjects with 
advanced solid tumors.  All three dose levels were well tolerated and no dose-limiting toxicities 
were observed.  This first in human study of pembrolizumab showed evidence of target 
engagement and objective evidence of tumor size reduction at all dose levels (1 mg/kg, 3 mg/kg 
and 10 mg/kg Q2W).  No MTD has been identified to date.  10.0 mg/kg Q2W, the highest dose 
tested in PN001, will be the dose and schedule utilized in Cohorts A, B, C and D of this protocol 
to test for initial tumor activity.  Recent data from other clinical studies within the pembrolizumab 
program has shown that a lower dose of pembrolizumab and a less frequent schedule may be 
sufficient for target engagement and clinical activity.
PK data analysis of pembrolizumab administered Q2W and Q3W showed slow systemic clearance, 
limited volume of distribution, and a long half-life (refer to IB).  Pharmacodynamic data (IL-2 
release assay) suggested that peripheral target engagement is durable (>21 days).  This early PK 
and pharmacodynamic data provides scientific rationale for testing a Q2W and Q3W dosing 
schedule.  
A population pharmacokinetic analysis has been performed using serum concentration time data 
from 476 patients. Within the resulting population PK model, clearance and volume parameters of 
pembrolizumab were found to be dependent on body weight. The relationship between clearance 
and body weight, with an allometric exponent of 0.59, is within the range observed for other 
antibodies and would support both body weight normalized dosing or a fixed dose across all body 
weights.  Pembrolizumab has been found to have a wide therapeutic range based on the melanoma 
indication.  The differences in exposure for a 200 mg fixed dose regimen relative to a 2 mg/kg 
Q3W body weight based regimen are anticipated to remain well within the established exposure 
margins of 0.5 – 5.0 for pembrolizumab in the melanoma indication. The exposure margins are 
based on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the proposed 
dose regimen of 2 mg/kg Q3W (i.e. 5-fold higher dose and exposure). The population PK 
evaluation revealed that there was no significant impact of tumor burden on exposure. In addition, 
exposure was similar between the NSCLC and melanoma indications. Therefore, there are no 
anticipated changes in exposure between different indication settings.
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in solid 
tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 mg/kg 
or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure-response relationships of 
pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 
3) the lack of effect of tumor burden or indication on distribution behavior of pembrolizumab (as 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
11assessed by the population PK model) and 4) the assumption that the dynamics of pembrolizumab 
target engagement will not vary meaningfully with tumor type.
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on 
simulations performed using the population PK model of pembrolizumab showing that the fixed 
dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those 
obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the 
exposure range established in melanoma as associated with maximal efficacy response and 3) will 
maintain individual patients exposure in the exposure range established in melanoma that are well 
tolerated and safe. 
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexity in the 
logistical chain at treatment facilities and reduce wastage.
5. PARTICIPANT SELECTION
5.1 Eligibility Criteria 
In order to be eligible for participation in this trial, the subject must:
1. Participants must have metastatic or locally advanced incurable anal cancer that has been 
histologically confirmed. Patients with locally advanced anal cancer must have had cancer 
recurrence after chemoradiation and must be unresectable.
2. There is no limit to the number of prior therapies.
3. Be willing and able to provide written informed consent/assent for the trial.
4. Be  18 years of age on day of signing informed consent.
5. Have measurable disease based on RECIST 1.1.  
6.Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor 
lesion.  Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to 
initiation of treatment on Day 1.  Subjects for whom newly-obtained samples cannot be 
provided (e.g. inaccessible or subject safety concern) may submit an archived specimen 
only upon agreement from the Sponsor.
7. Have a performance status of 0 or 1 on the ECOG Performance Scale (Appendix A).
8. Demonstrate adequate organ function as defined in 
Table 1, all screening labs must be performed within 10 days of treatment initiation.  Labs 
must meet eligibility criteria within 4 days of Cycle 1 Day 1.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
12Table 1  Adequate Organ Function Laboratory Values
System Laboratory Value
Hematological
Absolute neutrophil count (ANC) ≥1,500 /mcL
Platelets ≥80,000 / mcL
Hemoglobin ≥8.5 g/dL or ≥5.6 mmol/L 
Renal
Serum creatinine OR
Measured or calculateda creatinine 
clearance
(GFR can also be used in place of creatinine 
or CrCl)≤1.5 X upper limit of normal (ULN) OR
≥60 mL/min for subject with creatinine levels > 1.5 X institutional 
ULN
Hepatic
Serum total bilirubin ≤ 1.5 X ULN OR
Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 
1.5 ULN
AST (SGOT) and ALT (SGPT)≤ 2.5 X ULN  OR
≤ 5 X ULN for subjects with liver metastases
Albumin >2.8 mg/dL
Coagulation
International Normalized Ratio (INR) or 
Prothrombin Time (PT)
Activated Partial Thromboplastin Time 
(aPTT)≤1.5 X ULN unless subject is receiving anticoagulant therapy
as long as PT or PTT is within therapeutic range of intended use 
of anticoagulants
≤1.5 X ULN unless subject is receiving anticoagulant therapy
as long as PT or PTT is within therapeutic range of intended use 
of anticoagulants
aCreatinine clearance should be calculated per institutional standard.
12. Female subject of childbearing potential must have a negative urine or serum pregnancy 
within 72 hours prior to receiving the first dose of study medication.  If the urine test is 
positive or cannot be confirmed as negative, a serum pregnancy test will be required.  
13. Female subjects of childbearing potential must be willing to use 2 methods of birth control 
or be surgically sterile, or abstain from heterosexual activity for the course of the study 
through 120 days after the last dose of study medication (Reference Section 7.4).  Subjects 
of childbearing potential are those who have not been surgically sterilized or have not been 
free from menses for > 1 year. 
14. Male subjects must agree to use an adequate method of contraception starting with the first 
dose of study therapy through 120 days after the last dose of study therapy.
5.2 Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other 
form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 
Subjects requiring systemic steroids are excluded from the trial. The use of physiologic 
doses of corticosteroids may be approved after discussion with the sponsor.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
132. Has a known history of active TB (Bacillus Tuberculosis)
3. Hypersensitivity to pembrolizumab or any of its excipients.
4. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 
1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents 
administered more than 4 weeks earlier.
5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 
2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from 
adverse events due to a previously administered agent.
-Note:  Subjects with ≤ Grade 2 neuropathy and alopecia are an exception to this 
criterion and may qualify for the study.
-Note:  If subject received major surgery, they must wait ≥ 3 weeks prior to starting 
study treatment. They must have recovered adequately from the toxicity and/or 
complications from the intervention prior to starting therapy.  
6. Has a known additional malignancy that is progressing or requires active treatment.  
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin 
that has undergone potentially curative therapy or in situ cervical cancer.
7. Has known active central nervous system (CNS) metastases and/or carcinomatous 
meningitis.  Subjects with previously treated brain metastases may participate provided 
they are stable (without evidence of progression by imaging for at least four weeks prior to 
the first dose of trial treatment and any neurologic symptoms have returned to baseline), 
have no evidence of new or enlarging brain metastases, and are not using steroids for at 
least 7 days prior to trial treatment.  This exception does not include carcinomatous 
meningitis which is excluded regardless of clinical stability.  
8. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. 
with use of disease modifying agents, corticosteroids or immunosuppressive drugs). 
Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement 
therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic 
treatment. 
9. Has an active infection requiring systemic therapy.
10. Patients that require supplemental oxygen are excluded.
11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that 
might confound the results of the trial, interfere with the subject’s participation for the full 
duration of the trial, or is not in the best interest of the subject to participate, in the opinion 
of the treating investigator.  
12. Has known psychiatric or substance abuse disorders that would interfere with cooperation 
with the requirements of the trial.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
1413. Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the trial, starting with the pre-screening or screening visit through 
120 days after the last dose of trial treatment.
14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
15. HIV+ positive patients are eligible if their CD4+ count ≥ 300/μL and they have an 
undetectable viral load. In addition, they must be currently receiving Highly Active 
Antiretroviral Therapy (HAART) and be under the care of an Infectious Diseases specialist.
16. Patients with hepatitis B and hepatitis C must be under the care of viral hepatitis expert 
consultant. Patients with hepatitis B are required to be treated with anti-HBV treatment 
(e.g., entecavir). Patients with hepatitis C need to have received prior and/or ongoing 
hepatitis C treatment.
17. Has received a live vaccine within 30 days of planned start of study therapy.
Note:  Seasonal influenza vaccines for injection are generally inactivated flu vaccines and 
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated 
vaccines, and are not allowed.
18. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
5.3 Inclusion of Women and Minorities
Both men and women of all races and ethnic groups are eligible for this trial.
6. REGISTRATION PROCEDURES
6.1 General Guidelines for DF/HCC and DF/PCC Institutions
Institutions will register eligible participants in the Clinical Trials Management System (CTMS) 
OnCore. Registrations must occur prior to the initiation of protocol therapy. Any participant not 
registered to the protocol before protocol therapy begins will be considered ineligible and 
registration will be denied.
An investigator will confirm eligibility criteria and a member of the study team will complete the 
protocol-specific eligibility checklist.
Following registration, participants may begin protocol therapy. Issues that would cause treatment 
delays should be discussed with the Overall Principal Investigator (PI). If a participant does not 
receive protocol therapy following registration, the participant’s registration on the study must be 
canceled. Registration cancellations must be made in OnCore as soon as possible. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
156.2 Registration Process for DF/HCC and DF/PCC Institutions
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject Protocol 
Registration (SOP #: REGIST-101) must be followed.  
6.3 General Guidelines for Other Investigative Sites
Eligible participants will be entered on study centrally at Dana-Farber Cancer Institute by the 
Study Coordinator.  All sites should call the Study Coordinator at 617-632-6316 when a potential 
patient is identified to confirm the study status and enrollment availability.  Following registration, 
participants should begin protocol therapy within 5 days. Issues that would cause treatment delays 
should be discussed with the Overall PI.  If a participant does not receive protocol therapy 
following registration, the participant’s registration on the study must be canceled.  The Study 
Coordinator should be notified of cancellations as soon as possible.
6.4 Registration Process for Other Investigative Sites
To register a participant, the following documents should be completed by the research nurse or 
data manager and faxed or e-mailed to the Study Coordinator (617-582-7988 or 
mailto: KatherineA_Metayer@dfci.harvard.edu):
Copy of pathology report confirming diagnosis, laboratory results and baseline imaging 
report
Signed participant consent form
HIPAA authorization form
Eligibility Checklist
The research nurse or data manager at the participating site will then call or e-mail the Study 
Coordinator to verify eligibility.  To complete the registration process, the Coordinator will follow 
DF/HCC Standard Operating Procedure for Human Subject Research Titled Subject Protocol 
Registration (SOP #: REGIST-101) and register the participant on the protocol.  The coordinator 
will fax or e-mail the participant study number, and if applicable the dose treatment level, to the 
participating site.  The coordinator will also call the research nurse or data manager at the 
participating site and verbally confirm registration
7. TREATMENT PLAN
7.1 Trial Treatment
The treatment to be used in this trial is outlined below in 
Table 2
Table 2  Trial Treatment
Drug Dose/Potency Dose 
FrequencyRoute of 
AdministrationRegimen/Treatment 
PeriodUse
Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week 
cycleExperimental
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
167.1.1 Timing of Dose Administration
Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments 
have been completed as detailed on the Trial Flow Chart (Section 12).  Trial treatment may be 
administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative 
reasons.
All trial treatments will be administered on an outpatient basis.
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.  Sites 
should make every effort to target infusion timing to be as close to 30 minutes as possible.  
However, given the variability of infusion pumps from site to site, a window of -5 minutes and 
+10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab 
infusion fluid and administration of infusion solution (Appendix G).
7.2 Pre-Treatment Criteria
Pembrolizumab must be withheld for severe or life-threatening drug-related toxicities. Please see 
section 8.1 (Table 3) for specific instructions.
7.3 Concomitant Medications/Vaccinations (allowed & prohibited)
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during 
the ongoing trial.  If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or 
vaccination may be required.  The investigator should discuss any questions regarding this with 
the Overall PI at Dana-Farber Cancer Institute.  The final decision on any supportive therapy or 
vaccination rests with the investigator and/or the subject's primary physician.
 
7.3.1 Acceptable Concomitant Medications
All treatments that the investigator considers necessary for a subject’s welfare may be administered 
at the discretion of the investigator in keeping with the community standards of medical care.  All 
concomitant medication will be recorded on the case report form (CRF) including all prescription, 
over-the-counter (OTC), herbal supplements, and IV medications and fluids.  If changes occur 
during the trial period, documentation of drug dosage, frequency, route, and date may also be 
included on the CRF.
All concomitant medications received within 28 days before the first dose of trial treatment and 
30 days after the last dose of trial treatment should be recorded.  Concomitant medications 
administered after 30 days after the last dose of trial treatment should be recorded for SAEs and 
Events of Clinical Interest (ECIs)  as defined in Section 9.8.1.2.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
177.3.2 Prohibited Concomitant Medications
Subjects are prohibited from receiving the following therapies during the Treatment Phase 
(including retreatment for post-complete response relapse) of this trial:
Antineoplastic systemic chemotherapy or biological therapy 
Immunotherapy not specified in this protocol
Chemotherapy not specified in this protocol
Investigational agents other than pembrolizumab
Radiation therapy 
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may be allowed 
at the investigator’s discretion.  
Live vaccines within 30 days prior to the first dose of trial treatment and while participating 
in the trial.  Examples of live vaccines include, but are not limited to, the following: 
measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. 
Systemic glucocorticoids for any purpose other than to modulate symptoms from an event 
of clinical interest of suspected immunologic etiology.  The use of physiologic doses of 
corticosteroids may be approved after consultation with the Sponsor.
Subjects who, in the assessment by the investigator, require the use of any of the aforementioned 
treatments for clinical management should be removed from the trial.  Subjects may receive other 
medications that the investigator deems to be medically necessary.
The Exclusion Criteria describes other medications which are prohibited in this trial.
There are no prohibited therapies during the Post-Treatment Follow-up Phase.
7.4 Diet/Activity/Other Considerations
7.4.1 Diet
Subjects should maintain a normal diet unless modifications are required to manage an AE such 
as diarrhea, nausea or vomiting.
7.4.2 Contraception
Pembrolizumab may have adverse effects on a fetus in utero.  Furthermore, it is not known if 
pembrolizumab has transient adverse effects on the composition of sperm.  Non-pregnant, non-
breast-feeding women may be enrolled if they are willing to use 2 methods of birth control or are 
considered highly unlikely to conceive.  Highly unlikely to conceive is defined as 1) surgically 
sterilized, or 2) postmenopausal (a woman who is ≥45 years of age and has not had menses for 
greater than 1 year will be considered postmenopausal), or 3) not heterosexually active for the 
duration of the study.  The two birth control methods can be either two barrier methods or a barrier 
method plus a hormonal method to prevent pregnancy. Subjects should start using birth control 
from study Visit 1 throughout the study period up to 120 days after the last dose of study therapy. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
18The following are considered adequate barrier methods of contraception: diaphragm, condom (by 
the partner), copper intrauterine device, sponge, or spermicide.  Appropriate hormonal 
contraceptives will include any registered and marketed contraceptive agent that contains an 
estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular 
agents).
Subjects should be informed that taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the 
study they must adhere to the contraception requirement (described above) for the duration of the 
study and during the follow-up period defined in section 9.7-Reporting of Pregnancy and Lactation 
to the Sponsor and to Merck.  If there is any question that a subject will not reliably comply with 
the requirements for contraception, that subject should not be entered into the study.
7.4.3 Use in Pregnancy
If a subject inadvertently becomes pregnant while on treatment with pembrolizumab, the subject 
will immediately be removed from the study.  The site will contact the subject at least monthly 
and document the subject’s status until the pregnancy has been completed or terminated.  The 
outcome of the pregnancy will be reported to the Sponsor and to Merck without delay and within 
24 hours to the Sponsor and within 2 working days to Merck if the outcome is a serious adverse 
experience (e.g., death, abortion, congenital anomaly, or other disabling or life-threatening 
complication to the mother or newborn).  
The study investigator will make every effort to obtain permission to follow the outcome of the 
pregnancy and report the condition of the fetus or newborn to the Sponsor.   If a male subject 
impregnates his female partner the study personnel at the site must be informed immediately and 
the pregnancy reported to the Sponsor and to Merck and followed as described above and in 
Section 9.7.
7.4.4 Use in Nursing Women
It is unknown whether pembrolizumab is excreted in human milk.  Since many drugs are excreted 
in human milk, and because of the potential for serious adverse reactions in the nursing infant, 
subjects who are breast-feeding are not eligible for enrollment.
7.5 Criteria for Taking a Participant Off Protocol Therapy
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 
discretion of the investigator should any untoward effect occur.  In addition, a subject may be 
withdrawn by the investigator or the Sponsor if enrollment into the trial is inappropriate, the trial 
plan is violated, or for administrative and/or other safety reasons.  
A subject must be discontinued from the trial for any of the following reasons:
The subject or legal representative (such as a parent or legal guardian) withdraws consent.
Confirmed radiographic disease progression on two successive imaging studies
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
19Note: A subject may be granted an exception to continue on treatment with confirmed 
radiographic progression if clinically stable or clinically improved
Unacceptable adverse experiences as described in Section 9.0
Intercurrent illness that prevents further administration of treatment
Investigator’s decision to withdraw the subject
The subject has a confirmed positive serum pregnancy test
Noncompliance with trial treatment or procedure requirements
The subject is lost to follow-up
Completed 24 months of uninterrupted treatment with pembrolizumab or 35 
administrations of study medication, whichever is later.
Note: 24 months of study medication is calculated from the date of first dose. Subjects who 
stop pembrolizumab after 24 months may be eligible for up to one year of additional study 
treatment if they progress after stopping study treatment provided they meet the 
requirements detailed in Section 12.1.1.1.
Administrative reasons
The End of Treatment and Follow-up visit procedures are listed in Section 12 (Protocol Flow 
Chart). After the end of treatment, each subject will be followed for 30 days for adverse event 
monitoring (serious adverse events will be collected for 90 days after the end of treatment as 
described in Section 9.8).  Subjects who discontinue for reasons other than progressive disease 
will have post-treatment follow-up for disease status until disease progression, initiating a non-
study cancer treatment, withdrawing consent or becoming lost to follow-up.  After documented 
disease progression each subject will be followed by telephone for overall survival until death, 
withdrawal of consent, or the end of the study, whichever occurs first.
Discontinuation of Study Therapy after CR 
Discontinuation of treatment may be considered for subjects who have attained a confirmed CR 
that have been treated for at least 24 weeks with pembrolizumab and had at least two treatments 
with pembrolizumab beyond the date when the initial CR was declared.  Subjects who then 
experience radiographic disease progression may be eligible for up to one year of additional 
treatment with pembrolizumab via the Second Course Phase at the discretion of the investigator if 
no cancer treatment was administered since the last dose of pembrolizumab, the subject meets the 
safety parameters listed in the Inclusion/Exclusion criteria, and the trial is open.  Subjects will 
resume therapy at the same dose and schedule at the time of initial discontinuation.  Additional 
details are provided in Section 12.1.1.1.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
20A ODQ Treatment Ended/Off Study Form will be filled out when a participant is removed from 
protocol therapy. This form can be found on the ODQ website or obtained from the ODQ 
registration staff.
7.6 Clinical Criteria for Early Trial Termination
Early trial termination will be the result of the criteria specified below:
1. Quality or quantity of data recording is inaccurate or incomplete
2. Poor adherence to protocol and regulatory requirements
3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential health 
hazard to subjects
4. Plans to modify or discontinue the development of the study drug
In the event of Merck decision to no longer supply study drug, ample notification will be provided 
so that appropriate adjustments to subject treatment can be made.
7.7 Duration of Follow Up
After removal from protocol therapy, participants will be followed until death, lost to follow-up, 
or study closure, whichever occurs first. Participants removed from protocol therapy for 
unacceptable adverse event(s) will be followed until resolution or stabilization of the adverse 
event.
7.8 Criteria for Taking a Participant Off Study
Participants will be removed from study when any of the following criteria apply:
Lost to follow-up
Withdrawal of consent for data submission
Death
The reason for taking a participant off study, and the date the participant was removed, must be 
documented in the case report form (CRF).
For Centralized Subject Registrations, the research team submits a completed Off Treatment/Off 
Study form to ODQ when a participant comes off study. This form can be found on the ODQ 
website or obtained from the ODQ registration staff. 
For Decentralized Subject Registrations, the research team updates the relevant Off Treatment/Off 
Study information in OnCore. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
218. DOSING DELAYS/DOSE MODIFICATIONS
8.1 Dose Modification 
Adverse events (both non-serious and serious) associated with pembrolizumab exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first dose or 
several months after the last dose of treatment. Pembrolizumab must be withheld for drug-related 
toxicities and severe or life-threatening AEs as per Table 3 below. See Section 8.2.1 and Events 
of Clinical Interest Guidance Document for supportive care guidelines, including use of 
corticosteroids. Refer to Appendix B for more information on Events of Clinical Interest.
Table 3 Dose Modification Guidelines for Drug-Related Adverse Events
ToxicityHold 
Treatment 
For GradeTiming for Restarting Treatment Discontinue Subject
2-3Toxicity resolves to Grade 0-1.Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks. Diarrhea/Colitis
4 Permanently discontinue Permanently discontinue
2 Toxicity resolves to Grade 0-1 Toxicity does not resolve within 12 weeks of last dose.AST, ALT, or 
Increased Bilirubin3-4Permanently discontinue
(see exception below)1 Permanently discontinue
Type 1 diabetes 
mellitus (if new 
onset) or 
HyperglycemiaT1DM or 
3-4Hold pembrolizumab for new onset Type 1 
diabetes mellitus or Grade 3-4 
hyperglycemia associated with evidence of 
beta cell failure. Resume pembrolizumab when patients are clinically and 
metabolically stable.
2-4 Toxicity resolves to Grade 0-1 Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks.Hypophysitis
3 Toxicity resolves to Grade 0-1Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks.Hyperthyroidism 
4 Permanently discontinue Permanently discontinue
Hypothyroidism 2-4Therapy with pembrolizumab can be 
continued while treatment for the thyroid 
disorder is institutedTherapy with pembrolizumab can be continued while treatment for 
the thyroid disorder is instituted.
Infusion Reaction 3-4 Permanently discontinue Permanently discontinue
2 Toxicity resolves to Grade 0-1Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks.Pneumonitis
3-4 Permanently discontinue Permanently discontinue
2 Toxicity resolves to Grade 0-1Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks.Renal Failure or 
Nephritis
3-4 Permanently discontinue Permanently discontinue
3 or Severe Toxicity resolves to Grade 0-1Toxicity does not resolve within 12 weeks of last dose or inability to 
reduce corticosteroid to 10 mg or less of prednisone or equivalent per 
day within 12 weeks.All Other Drug-
Related Toxicity2
4 Permanently discontinue Permanently discontinue
Note: Permanently discontinue for any severe or Grade 3 drug-related AE that recurs or any life-threatening event.
1 For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by greater than or equal to 50% relative to baseline 
and lasts for at least 1 week then patients should be discontinued.
2 Patients with intolerable or persistent Grade 2 drug-related AE may hold study medication at physician discretion.  Permanently discontinue study drug for 
persistent Grade 2 adverse reactions for which treatment with study drug has been held, that do not recover to Grade 0-1 within 12 weeks of the last dose.  
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
22Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons not 
related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, and/or 
holidays). Subjects should be placed back on study therapy within 3 weeks of the scheduled 
interruption, unless otherwise discussed with the Sponsor. The reason for interruption should be 
documented in the patient's study record.
8.2 Rescue Medications & Supportive Care
8.2.1 Supportive Care Guidelines
Subjects should receive appropriate supportive care measures as deemed necessary by the treating 
investigator.  Suggested supportive care measures for the management of adverse events with 
potential immunologic etiology are outlined below and in greater detail in the Event of Clinical 
Interest (ECI) guidance document. Where appropriate, these guidelines include the use of oral or 
intravenous treatment with corticosteroids as well as additional anti-inflammatory agents if 
symptoms do not improve with administration of corticosteroids.   Note that several courses of 
steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. 
For each disorder, attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care. The treatment 
guidelines are intended to be applied when the investigator determines the events to be related to 
pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the investigator is instructed 
to follow the ECI reporting guidance but does not need to follow the treatment guidance (as 
outlined in the ECI guidance document). Refer to Section 8.1 for dose modification. Refer to 
Appendix B for more information on Events of Clinical Interest.
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. Suggested conditional procedures, as appropriate, 
can be found in the ECI guidance document.
Pneumonitis: 
oFor Grade 2 events, treat with systemic corticosteroids. When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
oFor Grade 3-4 events, immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory measures, as needed.
oAdd prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration.
Diarrhea/Colitis: 
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel 
perforation (such as peritoneal signs and ileus).  
oAll subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
23electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
oFor Grade 2 diarrhea/colitis  that persists greater than 3 days, administer oral 
corticosteroids. 
oFor Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous 
steroids followed by high dose oral steroids.  
oWhen symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis 
(DKA)
oFor T1DM or Grade 3-4 Hyperglycemia
Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3-4 hyperglycemia associated with metabolic acidosis or 
ketonuria. 
Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide. 
Hypophysitis:
oFor Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is 
tapered.
oFor Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by 
oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered.
Hyperthyroidism or Hypothyroidism: 
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated 
based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
oGrade 2 hyperthyroidism events (and Grade 3-4 hypothyroidism):
In hyperthyroidism, non-selective beta-blockers (e.g. propranolol) are 
suggested as initial therapy.
In hypothyroidism, thyroid hormone replacement therapy, with 
levothyroxine or liothyroinine, is indicated per standard of care.
oGrade 3-4 hyperthyroidism 
Treat with an initial dose of IV corticosteroid followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
24Hepatic:
oFor Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
Treat with IV or oral corticosteroids
oFor Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
oWhen symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.
Renal Failure or Nephritis:
oFor Grade 2 events, treat with corticosteroids.
oFor Grade 3-4 events, treat with systemic corticosteroids.
oWhen symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks. 
Management of Infusion Reactions: Signs and symptoms usually develop during or 
shortly after drug infusion and generally resolve completely within 24 hours of completion 
of infusion. 
Table  4 below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK-3475).
Table 4 Infusion Reaction Treatment Guidelines
NCI CTCAE Grade Treatment Premedication at subsequent 
dosing
Grade 1
Mild reaction; infusion interruption not 
indicated; intervention not indicatedIncrease monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator.None
Grade 2
Requires infusion interruption but 
responds promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated for 
< =24 hrsStop Infusion and monitor symptoms.
Additional appropriate medical therapy may 
include but is not limited to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator.
If symptoms resolve within one hour of stopping 
drug infusion, the infusion may be restarted at 50% 
of the original infusion rate (e.g., from 100 mL/hr 
to 50 mL/hr).  Otherwise dosing will be held until 
symptoms resolve and the subject should be 
premedicated for the next scheduled dose.
Subjects who develop Grade 2 toxicity despite 
adequate premedication should be 
permanently discontinued from further trial 
treatment administration.Subject may be premedicated 1.5h 
(± 30 minutes) prior to infusion of 
pembrolizumab (MK-3475) with:
Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).
Acetaminophen 500-1000 mg po (or 
equivalent dose of antipyretic).
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly responsive 
to symptomatic medication and/or brief 
interruption of infusion); recurrence of 
symptoms following initial 
improvement; hospitalization indicated 
for other clinical sequelae (e.g., renal 
impairment, pulmonary infiltrates)
Grade 4:Stop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Oxygen
PressorsNo subsequent dosing
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
25NCI CTCAE Grade Treatment Premedication at subsequent 
dosing
Life-threatening; pressor or ventilatory 
support indicatedCorticosteroids
Epinephrine
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator.
Hospitalization may be indicated.
Subject is permanently discontinued from 
further trial treatment administration.
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of drug 
administration.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
269. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS 
9.1 Expedited Adverse Event Reporting 
9.1.1 All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators 
in accordance with all applicable global laws and regulations.
9.1.2 Investigators must report to the Overall PI any serious adverse event (SAE) that occurs 
after the initial dose of study treatment, during treatment, or within 30 days of the last dose 
of treatment on the local institutional SAE form. 
9.1.3 For multi-institution studies where a DF/HCC investigator is serving as the Overall 
Principal Investigator, each participating institution must abide by the reporting 
requirements set by the DF/HCC. This applies to any medical event equivalent to an 
unexpected grade 2 or 3 with a possible, probable or definite attribution, unexpected grade 
4 toxicities, and grade 5 (death) regardless of study phase or attribution.
9.1.4 DF/HCC Expedited Reporting Guidelines
Investigative sites within DF/HCC will report AEs directly to the DFCI Office for Human 
Research Studies (OHRS) per the DFCI IRB reporting policy. 
Other investigative sites will report AEs to their respective IRB according to the local 
IRB’s policies and procedures in reporting adverse events. A copy of the submitted 
institutional AE form should be forwarded to the Overall PI within the timeframes detailed 
in the table below.  
DF/HCC Reportable AEs
AttributionGr. 2 & 3 AE
ExpectedGr. 2 & 3 AE 
UnexpectedGr. 4 AE Expected Gr. 4 AE
UnexpectedGr. 5 AE 
Expected or 
Unexpected
Unrelated
UnlikelyNot required Not required 5 calendar days#5 calendar days 24 hours*
Possible
Probable
DefiniteNot required 5 calendar days 5 calendar days#5 calendar days 24 hours*
# If listed in protocol as expected and not requiring expedited reporting, event does not need to be reported.
* For participants enrolled and actively participating in the study or for AEs occurring within 30 days of the last 
intervention, the AE should be reported within 1 business day of learning of the event.
The Overall PI will submit AE reports from outside institutions to the DFCI OHRS 
according to DFCI IRB policies and procedures in reporting adverse events. 
9.2 Expedited Reporting to the Food and Drug Administration (FDA)
The Overall PI, as study sponsor, will be responsible for all communications with the FDA. The 
Overall PI will report to the FDA, regardless of the site of occurrence, any serious adverse event 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
27that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by the FDA.
9.3 Expedited Reporting to Hospital Risk Management
Participating investigators will report to their local Risk Management office any participant safety 
reports or sentinel events that require reporting according to institutional policy. 
9.4 Routine Adverse Event Reporting
All Adverse Events must be reported in routine study data submissions to the Overall PI on the 
toxicity case report forms.  AEs reported through expedited processes (e.g., reported to the 
IRB, FDA, etc.) must also be reported in routine study data submissions.
9.5 Definition of an Adverse Event and Reporting of Adverse Events to Merck
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have 
to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease 
temporally associated with the use of a medicinal product or protocol-specified procedure, whether 
or not considered related to the medicinal product or protocol-specified procedure.  Any worsening 
(i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting 
condition that is temporally associated with the use of the Merck’s product, is also an adverse 
event.
Changes resulting from normal growth and development that do not vary significantly in frequency 
or severity from expected levels are not to be considered adverse events.  Examples of this may 
include, but are not limited to, teething, typical crying in infants and children and onset of menses 
or menopause occurring at a physiologically appropriate time.
Merck product includes any pharmaceutical product, biological product, device, diagnostic agent 
or protocol-specified procedure, whether investigational (including placebo or active comparator 
medication) or marketed, manufactured by, licensed by, provided by or distributed by Merck for 
human use.
Adverse events may occur during the course of the use of Merck product in clinical trials or within 
the follow-up period specified by the protocol, or prescribed in clinical practice, from overdose 
(whether accidental or intentional), from abuse and from withdrawal.
Adverse events may also occur in screened subjects during any pre-allocation baseline period as a 
result of a protocol-specified intervention, including washout or discontinuation of usual therapy, 
diet, placebo treatment or a procedure.
Progression of the cancer under study is not considered an adverse event unless it is considered to 
be drug related by the investigator.
All adverse events will be recorded from the time the consent form is signed through 90 days 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
28following cessation of treatment and at each examination on the Adverse Event case report 
forms/worksheets. The reporting timeframe for adverse events meeting any serious criteria is 
described in section 9.8.
9.6 Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor 
and to Merck
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater (≥5 times the indicated dose).  No specific information is available on the treatment of 
overdose of pembrolizumab. Appropriate supportive treatment should be provided if clinically 
indicated. In the event of overdose, the subject should be observed closely for signs of toxicity.  
Appropriate supportive treatment should be provided if clinically indicated.
If an adverse event(s) is associated with (“results from”) the overdose of a Merck product, the 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are 
met.
If a dose of Merck’s product meeting the protocol definition of overdose is taken without any 
associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non-
serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional overdose 
without adverse effect.”
All reports of overdose with and without an adverse event must be reported within 24 hours to the 
Sponsor and within 2 working days hours to Merck Global Safety. (Attn: Worldwide Product 
Safety; FAX 215 993-1220)
9.7 Reporting of Pregnancy and Lactation to the Sponsor and to Merck
Although pregnancy and lactation are not considered adverse events, it is the responsibility of 
investigators or their designees to report any pregnancy or lactation in a subject (spontaneously 
reported to them), including the pregnancy of a male subject's female partner that occurs during 
the trial or within 120 days of completing the trial completing the trial, or 30 days following 
cessation of treatment if the subject initiates new anticancer therapy, whichever is earlier.  All 
subjects and female partners of male subjects who become pregnant must be followed to the 
completion/termination of the pregnancy.  Pregnancy outcomes of spontaneous abortion, missed 
abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage 
and stillbirth must be reported as serious events (Important Medical Events).  If the pregnancy 
continues to term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor and within 2 working days to Merck 
Global Safety. (Attn: Worldwide Product Safety; FAX 215 993-1220)
9.8 Immediate Reporting of Adverse Events to the Sponsor and to Merck
9.8.1.1 Serious Adverse Events
A serious adverse event is any adverse event occurring at any dose or during any use of Merck’s 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
29product that:
Results in death;
Is life threatening;
Results in persistent or significant disability/incapacity;
Results in or prolongs an existing inpatient hospitalization;
Is a congenital anomaly/birth defect;
Is a new cancer (that is not a condition of the study);
Is associated with an overdose;
Is an other important medical event 
Refer to Table 6 for additional details regarding each of the above criteria.
Progression of the cancer under study is not considered an adverse event unless it results in 
hospitalization or death.
Any serious adverse event, or follow up to a serious adverse event, including death due to any 
cause other than progression of the cancer under study that occurs to any subject from the time the 
consent is signed through 90 days following cessation of treatment, or the initiation of new anti-
cancer therapy, whichever is earlier, whether or not related to Merck product, must be reported 
within 24 hours Merck Global Safety. 
Non-serious Events of Clinical Interest will be forwarded to Merck Global Safety and will be handled 
in the same manner as SAEs. 
Additionally, any serious adverse event, considered by an investigator who is a qualified physician 
to be related to Merck product that is brought to the attention of the investigator at any time outside 
of the time period specified in the previous paragraph also must be reported immediately to the 
Sponsor and to Merck.
SAE reports and any other relevant safety information are to be forwarded to the Merck Global 
Safety facsimile number:  +1-215-993-1220
A copy of all 15 Day Reports and Annual Progress Reports is submitted as required by FDA, 
European Union (EU), Pharmaceutical and Medical Devices agency (PMDA) or other local 
regulators. Investigators will cross reference this submission according to local regulations to the 
Merck Investigational Compound Number (IND, CSA, etc.) at the time of submission.  
Additionally investigators will submit a copy of these reports to Merck & Co., Inc. (Attn: 
Worldwide Product Safety; FAX 215 993-1220) at the time of submission to FDA.
All subjects with serious adverse events must be followed up for outcome.
9.8.1.2 Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Events of Clinical Interest (ECI) 
and must be recorded as such on the Adverse Event case report forms/worksheets and reported 
within 24 hours to the Sponsor and within 2 working days to Merck Global Safety. (Attn: 
Worldwide Product Safety; FAX 215 993-1220)
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
30Events of clinical interest for this trial include:
1.  An overdose of Merck product, as defined in Section 9.6 - Definition of an Overdose for This 
Protocol and Reporting of Overdose to the Sponsor, that is not associated with clinical symptoms 
or abnormal laboratory results. 
2.  An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal 
and an elevated total bilirubin lab value that is greater than or equal to 2X the upper limit of normal 
and, at the same time, an alkaline phosphatase lab value that is less than 2X the upper limit of 
normal, as determined by way of protocol-specified laboratory testing or unscheduled laboratory 
testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional 
evaluation for an underlying etiology.  The trial site guidance for assessment and follow up of 
these criteria can be found in the Investigator Trial File Binder (or equivalent).
3.  Additional adverse events:
A separate guidance document has been provided entitled “Event of Clinical Interest Guidance 
Document” (previously entitled, “Event of Clinical Interest and Immune-Related Adverse 
Event Guidance Document”).  This document can be found in Appendix B and provides 
guidance regarding identification, evaluation and management of ECIs and irAEs.  
ECIs (both non-serious and serious adverse events) identified in this guidance document from 
the date of first dose through 90 days following cessation of treatment, or 30 days after the 
initiation of a new anticancer therapy, whichever is earlier, need to be reported within 24 hours 
to the Sponsor and within 2 working days to Merck Global Safety. (Attn: Worldwide Product 
Safety; FAX 215 993-1220), regardless of attribution to study treatment, consistent with 
standard SAE reporting guidelines.
Subjects should be assessed for possible ECIs prior to each dose.  Lab results should be 
evaluated and subjects should be asked for signs and symptoms suggestive of an immune-
related event.  Subjects who develop an ECI thought to be immune-related should have 
additional testing to rule out other etiologic causes.  If lab results or symptoms indicate a 
possible immune-related ECI, then additional testing should be performed to rule out other 
etiologic causes.  If no other cause is found, then it is assumed to be immune-related.
9.8.2 Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which 
changes CTCAE grade over the course of a given episode will have each change of grade recorded 
on the adverse event case report forms/worksheets.
All adverse events regardless of CTCAE grade must also be evaluated for seriousness.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
31Table 6 Evaluating Adverse Events
An investigator, who is a qualified physician, will evaluate all adverse events as to:
V4.0 
CTCAE 
GradingGrade 1 Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation or 
hospitalization indicated; disabling; limiting self-care ADL.
Grade 4 Life threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE
Seriousness A serious adverse event is any adverse event occurring at any dose or during any use of Merck product that:
†Results in death; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: 
This does not include an adverse event that, had it occurred in a more severe form, might have caused death.); or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of 
stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization [including hospitalization for 
an elective procedure] for a preexisting condition which has not worsened does not constitute a serious adverse event.); or
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or
Is a new cancer; (that is not a condition of the study) or
Is an overdose  (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event. 
An overdose that is not associated with an adverse event is considered a non-serious event of clinical interest and must be reported within 
24 hours.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a 
serious adverse event when, based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed previously (designated above by a †).
Duration Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Merck product to be discontinued?
Relationship 
to test drug Did the Merck product cause the adverse event? The determination of the likelihood that the Merck product caused the adverse event will 
be provided by an investigator who is a qualified physician. The investigator’s signed/dated initials on the source document or worksheet 
that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the 
investigator in assessing the likelihood of a relationship between the test drug and the adverse event based upon the available information. 
The following components are to be used to assess the relationship between the Merck product and the AE; the greater the correlation 
with the components and their respective elements (in number and/or intensity), the more likely the Merck product caused the adverse event 
(AE):
Exposure Is there evidence that the subject was actually exposed to the Merck product such as: reliable history, acceptable 
compliance assessment (pill count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in 
bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Merck product? 
Is the time of onset of the AE compatible with a drug-induced effect (applies to trials with investigational medicinal 
product)?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host 
or environmental factors
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
3210. PHARMACEUTICAL  INFORMATION
A list of the adverse events and potential risks associated with the investigational or other agents 
administered in this study can be found in Appendix B.
10.1 Investigational Product 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records 
and ensure appropriate supply, storage, handling, distribution and usage of investigational product 
in accordance with the protocol and any applicable laws and regulations.
Clinical Supplies will be provided by Merck as summarized in Table 7.
Table 7  Product Descriptions
Product Name & Potency Dosage Form
Pembrolizumab 50 mg Lyophilized Powder for Injection
Pembrolizumab 100 mg/ 4mL Solution for InjectionRelationship The following components are to be used to assess the relationship between the test drug and the AE: (continued)
to Merck 
product
(continued) Dechallenge Was the Merck product discontinued or dose/exposure/frequency reduced?
If yes, did the AE resolve or improve?
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved 
despite continuation of the Merck product; or (3) the trial is a single-dose drug trial); or (4) Merck product(s) is/are only 
used one time.)
Rechallenge Was the subject re-exposed to the Merck product in this study?
If yes, did the AE recur or worsen?
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a 
single-dose drug trial); or (3) Merck product(s) is/are used only one time).
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH 
MAY HAVE BEEN CAUSED BY THE MERCK PRODUCT, OR IF REEXPOSURE TO THE MERCK PRODUCT 
POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST 
BE APPROVED IN ADVANCE BY THE U.S. CLINICAL MONITOR AS PER DOSE MODIFICATION GUIDELINES 
IN THE PROTOCOL.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Merck product or 
drug class pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best 
clinical judgment, including consideration of the above elements.
Record one of the following Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Merck product 
relationship).
Yes, there is a reasonable 
possibility of Merck product 
relationship.There is evidence of exposure to the Merck product.  The temporal sequence of the AE onset relative to the administration 
of the Merck product is reasonable.  The AE is more likely explained by the Merck product than by another cause.
No, there is not a reasonable 
possibility Merck product 
relationshipSubject did not receive the Merck product OR temporal sequence of the AE onset relative to administration of the Merck 
product is not reasonable OR there is another obvious cause of the AE.  (Also entered for a subject with overdose without 
an associated AE.)
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
3310.2 Packaging and Labeling Information
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.
10.3 Clinical Supplies Disclosure
This trial is open-label; therefore, the subject, the trial site personnel, the Sponsor and/or designee 
are not blinded to treatment. Drug identity (name, strength) is included in the label text; random 
code/disclosure envelopes or lists are not provided.
10.4 Storage and Handling Requirements
Clinical supplies must be stored in a secure, limited-access location under the storage conditions 
specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the trial 
site.
Clinical supplies may not be used for any purpose other than that stated in the protocol.
10.5 Ordering
Investigative sites will order and acquire Pembrolizumab directly from Merck per Appendix F, 
Section 4 (Data and Safety Monitoring Plan).
10.6 Returns and Reconciliation
The investigator is responsible for keeping accurate records of the clinical supplies received from 
Merck or designee, the amount dispensed to the subjects and the amount remaining at the 
conclusion of the trial. 
Upon completion or termination of the study, all unused and/or partially used investigational 
product will be destroyed at the site per institutional policy. It is the Investigator’s responsibility 
to arrange for disposal of all empty containers, provided that procedures for proper disposal 
have been established according to applicable federal, state, local and institutional guidelines and 
procedures, and provided that appropriate records of disposal are kept.
11. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES
11.1 Biomarker Studies
11.1.1 Pre-treatment Tumor Biopsies
All patients with tumors that can be safely biopsied are required to undergo a pretreatment biopsy. 
Biopsy tissues will be collected and fixed by 10% neutral buffered formalin overnight, dehydrated 
and paraffin embedded. The paraffin blocks should be sent to the Coordinating Center at the 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
34following address:
Katherine Metayer 
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 1B-16
Boston, MA 02215
Ph: 617-632-6746
Please alert the Coordinating Center via email and provide a tracking number for the shipment: 
KatherineA_Metayer@dfci.harvard.edu
This fresh pretreatment tumor biopsy will allow us to analyze immunohistochemically the tumor 
and surrounding immune-infiltrate for PD-L1, PD-L2 and PD1 expression. Since human 
papillomavirus (HPV) infection is strongly associated with anal cancer, we will also utilize 
immunohistochemistry to evaluate p16 expression, a well-established surrogate marker of HPV 
infection (Alemany et al., 2015; Serup-Hansen et al., 2014).  
For patients treated at Dana-Farber Cancer Institute (DFCI), we will also use this biopsy to perform 
additional immune characterization.  Biopsy tissues will be collected and fixed by 10% neutral 
buffered formalin overnight, dehydrated and paraffin embedded. Four-micrometer-thick sections 
will be cut. The paraffin blocks and unstained slides will be stored at room temperature.  In 
collaboration with the Core laboratory at Dana-Farber Cancer Institute, we will utilize digital 
spatial profiling (assessing IHC biomarkers and RNA expression patterns) of the tumor samples 
to assess the tumor microenvironment. By analyzing the differences between responding and 
resistant patients, this will help us to better understand mechanisms of sensitivity and resistance to 
pembrolizumab.
11.1.2 Analysis of Circulating Peripheral Blood Mononuclear Cells (PBMCs):  
We will isolate PBMCs at initiation of pembrolizumab therapy and at serial time points during 
pembrolizumab therapy.  PBMCs will be isolated prior to the administration of pembrolizumab on 
day 1 of the first three cycles (for the initial collection this can occur either at screening or prior to 
treatment on C1D1). Following cycle 3, PBMCs will be collected on day 1 of every other treatment 
cycle. PBMCs will also be collected, if possible, on the visit when the patient is taken off the trial. 
Leftover specimens will be banked for future use by the Coordinating Center.
PBMCs will be processed and frozen for later batched flow cytometric analysis.  Peripheral blood 
mononuclear cells (PBMCs) will be collected from whole blood to assess immune cell populations. 
Surface staining with a panel of antibodies (CD3, CD4, CD8, CD25, FoxP3, CD11c, CD83, CD86, 
CD56) and intracytoplasmatic cytokine staining, followed by flow cytometry will be performed in 
order to identify different T cell populations, their activation status, and the production of different 
cytokines as well as other immune cell populations as described below:
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
35
Peripheral Blood Mononuclear Cell (PBMC) Specimens:
Samples will be drawn by an experienced phlebotomist or research nurse. Blood samples 
may be drawn either peripherally or via central line. Each site will be responsible for 
ordering their own laboratory supplies and shipping materials for the specimens. Shipping 
costs and supplies will be covered by the protocol budget. Specimens will be stored at the 
participating site until shipping arrangements have been made to the Coordinating Center.
Approximately 5-7 ml of blood for PBMC specimens will be collected in heparin treated 
(green top) tubes.  Samples will be collected prior to the administration of pembrolizumab 
on Day 1 of the first three cycles. Following Cycle 3, samples will be collected on Day 1 
of every other treatment cycle.
Instructions for PBMC Specimens:
1. Spin green-cap tubes (heparin treated tubes) at 1500 rpm for 10 min. 
2. Aspirate 2 ml plasma/tube and aliquot into 4 tubes (Corning, 430488) 
3. Pour all blood from green cap tubes into a 50 ml conical tube with maximum 
amount of 25 ml. 
4. Dilute blood 1:1 with PBS. e. Add 12 ml ficoll-paque (Cat# 17-1440-03; GE 
Healthcare) per a 50 ml conical tube. 
5. Slowly and gently layer the diluted blood on the ficoll-paque of the tube with 
maximum 35 ml. 
6. Centrifuge the tube at 1900 rpm for 20 min at room temperature with slow 
acceleration (#3) and deceleration (#3) in a Sorvall Legend centrifuge. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
367. Aspirate the PBMC layer between upper part (diluted plasma) and middle part 
(ficoll-paque) and transferring into a 50 ml conical tube. The lower part is 
composed of red blood cells. 
8. Dilute the collected PBMC at least 1:2 with PBS
9. Centrifuge the tube at 1500 rpm for 5 min at room temperature. 
10. Wash PBMC pellet with PBS once. 
11. Store the 5 × 106 cells/cryo vial in 300-500 µl of Fetal Bovine Serum plus 15% 
DMSO
12. Samples will be frozen at -70C until shipment is arranged to the Coordinating 
Center.
Samples will be shipped to the Coordinating Center at the following address:
Katherine Metayer
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 1B-16
Boston, MA 02215
Ph: 617-632-6316
All PBMC Cryovials will be labeled as follows:
Protocol Number
Subject Initials and Study ID #
Date of Collection
Contents: PBMC or Plasma
Please alert the Coordinating Center via email and provide a tracking number for the shipment: 
KatherineA_Metayer@dfci.harvard.edu
11.1.3 Analysis of Circulating Immune Markers: 
In parallel to PBMC isolation, we will also collect plasma at multiple time points through the 
course of pembrolizumab therapy. Plasma samples will be isolated prior to the administration of 
pembrolizumab on day 1 of the first three cycles. Following cycle 3, plasma samples will be 
collected on day 1 of every other treatment cycle. A plasma sample will also be collected, if 
possible, on the visit when the patient is taken off the trial. Plasma will be frozen and later 
analyzed.
We will analyze the serial plasma samples with markers of circulating tumor-tissue-modified HPV 
DNA (Naveris NavDx assay). We will use these data to correlate with recurrence of disease and 
to correlate with tumor response to pembrolizumab. These experiments will help us establish 
whether a liquid biopsy can predict responsiveness or the response kinetics to pembrolizumab.
If a sufficient volume of sample remains, in batches by DFCI’s immune-oncology core laboratory 
(led by Dr. Steve Hodi), we will analyze a panel of cytokines and chemokines using Luminex 
cytokine assay. Changes in cytokine production in immune cell subsets as a function of treatment 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
37will be determined by ELISA and intracellular cytokine staining. Absolute lymphocyte count 
(ALC) will be monitored.
Plasma Specimens:
Samples will be drawn by an experienced phlebotomist or research nurse. Blood samples 
may be drawn either peripherally or via central line. Each site will be responsible for 
ordering their own laboratory supplies and shipping materials for the specimens. Shipping 
costs and supplies will be covered by the protocol budget. Specimens will be stored at the 
participating site until shipping arrangements have been made to the Coordinating Center.
Approximately 5-7 ml of blood for plasma-based studies will be collected in EDTA (purple 
top) tubes. Samples will be collected prior to the administration of pembrolizumab on Day 
1 of the first three cycles. Following Cycle 3, samples will be collected on Day 1 of every 
other treatment cycle.
Instructions for Plasma Specimens:
Invert tube several times to assure complete mixing of anticoagulant (EDTA) and 
immediately centrifuge in a clinical centrifuge at 3,000 r.p.m. for 10 minutes at room 
temperature. Plasma should be aspirated without disturbing cells, aliquoted in 3 cryogenic 
vials, and frozen at –70C until shipment is arranged to the coordinating center.
All Plasma Cryovials will be labeled as follows:
Protocol Number
Subject Initials and Study ID #
Date of Collection
Contents: PBMC or Plasma
Samples will be shipped to the Coordinating Center at the following address:
Katherine Metayer
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 1B-16
Boston, MA 02215
Ph: 617-632-6316
Please alert the Coordinating Center via email and provide a tracking number for the shipment: 
KatherineA_Metayer@dfci.harvard.edu
11.1.4 Post-treatment Tumor Biopsies in Patients with Acquired Resistance to 
Pembrolizumab
Patients that develop acquired resistance to pembrolizumab will be encouraged to undergo an 
optional post-treatment biopsy. This biopsy will allow us to study mechanisms of resistance to 
pembrolizumab. To do this, we utilize the immune characterization techniques described above.
Biopsy tissues will be collected and fixed by 10% neutral buffered formalin overnight, dehydrated 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
38and paraffin embedded. The paraffin blocks should be sent to the Coordinating Center at the 
following address:
Katherine Metayer
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 1B-16
Boston, MA 02215
Ph: 617-632-6316
Please alert the Coordinating Center via email and provide a tracking number for the shipment: 
KatherineA_Metayer@dfci.harvard.edu
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
3912.STUDY CALENDAR AND VISIT REQUIREMENTS
Trial Period:Screenin
g Phase Treatment CyclesEnd of 
TreatmentPost-
Treatment
To be repeated beyond 8 
cycles
Treatment Cycle/Title:Main 
Study 
Screening 
(Visit 2) 1 2 3 4 5 6 7 8 DisconSafety 
Follow-upSurvival 
Follow-Up
Scheduling Window (Days): -28 to -1 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At time of 
Discon30 days 
post disconEvery 12 
weeks 
Administrative Procedures
Informed Consent X
Inclusion/Exclusion Criteria Xg
Demographics and Medical History X
Prior and Concomitant Medication Review X X (to be reviewed throughout treatment period)
Trial Treatment Administration X X X X X X X X
Survival Status X X X
Clinical Procedures/Assessments
Review Adverse Events X X X X X X X X X X X l
Full Physical Examination X X X X X X X X X
Vital Signs and Weight X X X X X X X X X
ECOG Performance Status X X X X X X X X X
Laboratory Procedures/Assessments: analysis performed by LOCAL laboratory
Pregnancy Test – Urine or Serum b-HCGeXiXiXiXiXiXiXiXiXiXi
PT/INR and aPTT Xh
CBC with Differential XhX X X X X X X X
Comprehensive Serum Chemistry PanelfXhX X X X X X X X
Urinalysis Xh
T3, FT4 and TSH XhX X X Xa
HIV and Hepatitis Testing X
Efficacy Measurements
Tumor Imaging XbX Xc
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood
Archival or Newly Obtained Tissue 
Collection j X Xd
Correlative Studies Blood Collection XmX X X X XkX
a: Beyond the 8th cycle TSH can be checked every 2-3 cycles at the treating investigators discretion
b: Baseline scans need to be obtained within 21 days of the start of pembrolizumab
c:. After cycle 12, restaging scans can be performed every 3-4 cycles at the discretion of the treating investigator.
d: Patients that initially responded to pembrolizumab can undergo an optional tumor biopsy at the end of the trial
e: Only for women of child-bearing potential
f: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total protein, 
SGOT [AST], SGPT [ALT], sodium.
g: Labs must meet eligibility criteria sometime between day -4 and day 1 of the trial
h: Labs for screening are to be performed within 10 days prior to the first dose of trial treatment
i: For women of reproductive potential, a serum pregnancy test should be performed within 72 hours prior to each cycle of trial 
treatment and 30 days post treatment. Pregnancy tests should be repeated if required by local guidelines.
j: Tissue may be obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. If a newly obtained sample cannot be 
provided (e.g. inaccessible or subject safety concern), an archival specimen may be submitted upon agreement from the Sponsor.
k: After Cycle 3, Correlative Studies Blood Collection will take place every other cycle.
l: Adverse events to be reported until 90 days post-treatment
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
40m: Baseline correlative blood can be collected either during screening or pre-dose on C1D1
12.1 Survival Follow-up
Once a subject experiences confirmed disease progression or starts a new anti-cancer therapy, the 
subject moves into the survival follow-up phase and should be contacted by telephone every 12 
weeks to assess for survival status until death, withdrawal of consent, or the end of the study, 
whichever occurs first. 
12.1.1.1 Second Course Phase (Retreatment Period)
Subjects who stop pembrolizumab with SD or better may be eligible for up to one year of 
additional pembrolizumab therapy if they progress after stopping study treatment.  This 
retreatment is termed the Second Course Phase of this study and is only available if the study 
remains open and the subject meets the following conditions:
Either 
oStopped initial treatment with pembrolizumab after attaining an investigator-
determined confirmed CR according to RECIST 1.1, and
Was treated for at least 24 weeks with pembrolizumab before discontinuing 
therapy
Received at least two treatments with pembrolizumab beyond the date when the 
initial CR was declared
OR
oHad SD, PR or CR and stopped pembrolizumab treatment after 24 months of study 
therapy for reasons other than disease progression or intolerability
AND
Experienced an investigator-determined confirmed radiographic disease progression after 
stopping their initial treatment with pembrolizumab
Did not receive any anti-cancer treatment since the last dose of pembrolizumab
Has a performance status of 0 or 1 on the ECOG Performance Scale
Demonstrates adequate organ function as detailed in Section 5.1
Female subject of childbearing potential should have a negative serum or urine pregnancy 
test within 72 hours prior to receiving retreatment with study medication.  
Female subject of childbearing potential should be willing to use 2 methods of birth control 
or be surgically sterile, or abstain from heterosexual activity for the course of the study 
through 120 days after the last dose of study medication (Reference Section 6.3.2).  
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
41Subjects of child bearing potential are those who have not been surgically sterilized or have 
been free from menses for > 1 year. 
Male subject should agree to use an adequate method of contraception starting with the 
first dose of study therapy through 120 days after the last dose of study therapy.  
Does not have a history or current evidence of any condition, therapy, or laboratory 
abnormality that might interfere with the subject’s participation for the full duration of the 
trial or is not in the best interest of the subject to participate, in the opinion of the treating 
investigator.
Subjects who restart treatment will be retreated at the same dose and dose interval as when they 
last received pembrolizumab.  Treatment will be administered for up to one additional year.
Visit requirements are outlined in Section 12 – Trial Flow Chart.
13. MEASUREMENT OF EFFECT
13.1 Antitumor Effect – Solid Tumors
For the purposes of this study, participants should be re-evaluated for response every 9 weeks (3 
cycles) up to cycle 7. After cycle 12, restaging scans can be performed every 3-4 cycles at the 
discretion of the treating investigator.
Response and progression will be evaluated in this study using the new international criteria 
proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) 
[Eur J Ca 45:228-247, 2009].  Changes in the largest diameter (unidimensional measurement) of 
the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the 
RECIST criteria.
13.1.1 Definitions
Evaluable for Target Disease response.  Only those participants who have measurable 
disease present at baseline, have received at least one cycle of therapy, and have had their 
disease re-evaluated will be considered evaluable for target disease response.  These 
participants will have their response classified according to the definitions stated below.  
(Note:  Participants who exhibit objective disease progression prior to the end of cycle 1 
will also be considered evaluable.)
Evaluable Non-Target Disease Response.  Participants who have lesions present at baseline 
that are evaluable but do not meet the definitions of measurable disease, have received at 
least one cycle of therapy, and have had their disease re-evaluated will be considered 
evaluable for non-target disease.  The response assessment is based on the presence, 
absence, or unequivocal progression of the lesions. 
13.1.2 Disease Parameters
Measurable disease.  Measurable lesions are defined as those that can be accurately 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
42measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm by chest 
x-ray or ≥10 mm with CT scan, MRI, or calipers by clinical exam.  All tumor measurements 
must be recorded in millimeters (or decimal fractions of centimeters).
Note: Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable. 
Malignant lymph nodes.  To be considered pathologically enlarged and measurable, a 
lymph node must be ≥15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow-up, only 
the short axis will be measured and followed.
Non-measurable disease.  All other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), 
are considered non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, 
abdominal masses (not followed by CT or MRI), and cystic lesions are all considered non-
measurable.
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should 
not be considered as malignant lesions (neither measurable nor non-measurable) since they 
are, by definition, simple cysts.
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-
cystic lesions are present in the same participant, these are preferred for selection as target 
lesions.
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target lesions 
and recorded and measured at baseline.  Target lesions should be selected on the basis of 
their size (lesions with the longest diameter), be representative of all involved organs, but 
in addition should be those that lend themselves to reproducible repeated measurements. It 
may be the case that, on occasion, the largest lesion does not lend itself to reproducible 
measurement in which circumstance the next largest lesion which can be measured 
reproducibly should be selected. A sum of the diameters (longest for non-nodal lesions, 
short axis for nodal lesions) for all target lesions will be calculated and reported as the 
baseline sum diameters. If lymph nodes are to be included in the sum, then only the short 
axis is added into the sum. The baseline sum diameters will be used as reference to further 
characterize any objective tumor regression in the measurable dimension of the disease. 
Non-target lesions.  All other lesions (or sites of disease) including any measurable lesions 
over and above the 5 target lesions should be identified as non-target lesions and should 
also be recorded at baseline. Measurements of these lesions are not required, but the 
presence, absence, or in rare cases unequivocal progression of each should be noted 
throughout follow up. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
4313.1.3 Methods for Evaluation of Disease
All measurements should be taken and recorded in metric notation using a ruler, calipers, or a 
digital measurement tool.  All baseline evaluations should be performed as closely as possible to 
the beginning of treatment and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam. 
Clinical lesions. Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and ≥10 mm in diameter as 
assessed using calipers (e.g., skin nodules).  In the case of skin lesions, documentation by 
color photography, including a ruler to estimate the size of the lesion, is recommended. 
Chest x-ray.  Lesions on chest x-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung; however, CT is preferable. 
Conventional CT and MRI. This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT thickness is 5mm or less. If CT scans have slice thickness 
greater than 5 mm, the minimum size of a measurable lesion should be twice the slice 
thickness. MRI is also acceptable in certain situations (e.g. for body scans).  
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; 
however, there are many image acquisition variables involved in MRI, which greatly impact image 
quality, lesion conspicuity, and measurement.  Furthermore, the availability of MRI is variable 
globally.  As with CT, if an MRI is performed, the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, 
as with CT, the modality used at follow-up should be the same as was used at baseline and the 
lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the 
RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body 
parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition 
protocol should be followed as closely as possible to prior scans.  Body scans should be performed 
with breath-hold scanning techniques, if possible.
FDG-PET. While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis 
of FDG-PET imaging can be identified according to the following algorithm: 
(a) Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of 
PD based on a new lesion.
(b)  No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive 
FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is 
PD.  If the positive FDG-PET at follow-up is not confirmed as a new site of disease on 
CT, additional follow-up CT  scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG-
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
44PET scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing site of 
disease on CT that is not progressing on the basis of the anatomic images, this is not 
PD.
(c)  FDG-PET may be used to upgrade a response to a CR in a manner similar to a 
biopsy in cases where a residual radiographic abnormality is thought to represent 
fibrosis or scarring.  The use of FDG-PET in this circumstance should be prospectively 
described in the protocol and supported by disease-specific medical literature for the 
indication.  However, it must be acknowledged that both approaches may lead to false 
positive CR due to limitations of FDG-PET and biopsy resolution/sensitivity.
Note:  A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image.
PET-CT. At present, the low dose or attenuation correction CT portion of a combined PET-
CT is not always of optimal diagnostic CT quality for use with RECIST measurements.  
However, if the site can document that the CT performed as part of a PET-CT is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of 
the PET-CT can be used for RECIST measurements and can be used interchangeably with 
conventional CT in accurately measuring cancer lesions over time.  Note, however, that 
the PET portion of the CT introduces additional data which may bias an investigator if it 
is not routinely or serially performed.  
MIBG (meta-iodobenzylguanidine).The following is recommended, to assure high 
quality images are obtained. 
Patient preparation: Iodides, usually SSKI (saturated solution of potassium iodide), are 
administered to reduce thyroidal accumulation of free radioiodine, preferably 
beginning the day prior to injection and continuing for 3 additional days (4 days total). 
For infants and children, one drop t.i.d. is sufficient, for adolescents 2 drops t.i.d., and 
for adults 3 drops t.i.d. Participants and/or parents are asked about exposure to potential 
interfering agents. If none is noted, an indwelling intravenous line is established. The 
dose of MIBG is administered by slow intravenous injection over 90 seconds. 
Images from the head to the distal lower extremities should be obtained. 
I-123MIBG scintigraphy is performed to obtain both planar and tomographic images. 
Planar: Anterior and posterior views from the top of the head to the proximal lower 
extremities are obtained for 10 minutes at 24 hours and occasionally at 48 hours 
following injection of 10 mCi/1.7 square meters of body surface area (~150 μCi/kg, 
maximum 10 mCi). Anterior views of the distal lower extremities are adequate. A large 
field of view dual head gamma camera with low energy collimators is preferred. 
SPECT: Most participants receiving I-123 MIBG also undergo SPECT at 24 hours, 
using a single or multi-headed camera with a low energy collimator. The camera is 
rotated through 360 degrees, 120 projections at 25 seconds per stop. Data are 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
45reconstructed using filtered back projections with a Butterworth filter and a cut off 
frequency of 0.2-0.5. SPECT/CT may be performed at institutions with this capacity.
Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be used as 
a method of measurement. Ultrasound examinations cannot be reproduced in their entirety 
for independent review at a later data and, because they are operator dependent, it cannot 
be guaranteed that the same technique and measurements will be taken from one 
assessment to the next. If new lesions are identified by ultrasound in the course of the study, 
confirmation by CT or MRI is advised. If there is concern about radiation exposure from 
CT, MRI may be used instead of CT in selected instances. 
Endoscopy, Laparoscopy. The utilization of these techniques for objective tumor 
evaluation is not advised. However, such techniques may be useful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials where 
recurrence following complete response (CR) or surgical resection is an endpoint.
Tumor markers. Tumor markers alone cannot be used to assess response. If markers are 
initially above the upper normal limit, they must normalize for a participant to be 
considered in complete clinical response.  Specific guidelines for both CA-125 response 
(in recurrent ovarian cancer) and PSA response (in recurrent prostate cancer) have been 
published [JNCI 96:487-488, 2004; J Clin Oncol 17, 3461-3467, 1999; J Clin Oncol 
26:1148-1159, 2008].  In addition, the Gynecologic Cancer Intergroup has developed CA-
125 progression criteria which are to be integrated with objective tumor assessment for use 
in first-line trials in ovarian cancer [JNCI 92:1534-1535, 2000].
Cytology, Histology. These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).
The cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or stable 
disease is mandatory to differentiate between response or stable disease (an effusion may 
be a side effect of the treatment) and progressive disease.
13.1.4 Response Criteria
13.1.4.1 Evaluation of Target Lesions
Complete Response (CR):  Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non-target) must have reduction in short axis to <10 mm.
Partial Response (PR):  At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters.
Progressive Disease (PD):  At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study).  In addition to the relative increase of 20%, the sum must 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
46also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one 
or more new lesions is also considered progressions).
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study.
13.1.4.2 Evaluation of Non-Target Lesions
Complete Response (CR):  Disappearance of all non-target lesions and normalization 
of tumor marker level.  All lymph nodes must be non-pathological in size (<10 mm 
short axis).
Note:  If tumor markers are initially above the upper normal limit, they must normalize 
for a patient to be considered in complete clinical response.
Non-CR/Non-PD:  Persistence of one or more non-target lesion(s) and/or maintenance 
of tumor marker level above the normal limits.
Progressive Disease (PD):  Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  Unequivocal progression should not 
normally trump target lesion status.  It must be representative of overall disease status 
change, not a single lesion increase.    
Although a clear progression of “non-target” lesions only is exceptional, the opinion of 
the treating physician should prevail in such circumstances, and the progression status 
should be confirmed at a later time by the review panel (or Principal Investigator).
13.1.4.3 Evaluation of New Lesions
The finding of a new lesion should be unequivocal (i.e. not due to difference in scanning technique, 
imaging modality, or findings thought to represent something other than tumor (for example, some 
‘new’ bone lesions may be simply healing or flare of pre-existing lesions). However, a lesion 
identified on a follow-up scan in an anatomical location that was not scanned at baseline is 
considered new and will indicate PD. If a new lesion is equivocal (because of small size etc.), 
follow-up evaluation will clarify if it truly represents new disease and if PD is confirmed, 
progression should be declared using the date of the initial scan on which the lesion was 
discovered.
13.1.4.4 Evaluation of Best Overall Response
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  The patient's best response assignment will depend on the 
achievement of both measurement and confirmation criteria.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
47For Participants with Measurable Disease (i.e., Target Disease)
Target 
LesionsNon-Target 
LesionsNew 
LesionsOverall 
ResponseBest Overall Response when 
Confirmation is Required*
CR CR No CR >4 wks Confirmation**
CR Non-CR/Non-
PDNo PR
CR Not evaluated No PR
PR Non-CR/Non-
PD/not 
evaluatedNo PR>4 wks Confirmation**
SD Non-CR/Non-
PD/not 
evaluatedNo SDDocumented at least once >4 
wks from baseline**
PD Any Yes or No PD
Any PD*** Yes or No PD
Any Any Yes PDno prior SD, PR or CR
 See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.
**        Only for non-randomized trials with response as primary endpoint.
***      In exceptional circumstances, unequivocal progression in non-target lesions may be
            accepted as disease progression.
Note:  Participants with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported as “symptomatic deterioration.”  Every effort should be made to document the 
objective progression even after discontinuation of treatment.
For Participants with Non-Measurable Disease (i.e., Non-Target Disease)
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PD*
Not all evaluated No not evaluated
Unequivocal PD Yes or No PD
Any Yes PD
 ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised
13.1.5 Duration of Response
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date 
that recurrent or progressive disease is objectively documented (taking as reference for 
progressive disease the smallest measurements recorded since the treatment started, or 
death due to any cause. Participants without events reported are censored at the last disease 
evaluation).
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
48Duration of overall complete response: The duration of overall CR is measured from the 
time measurement criteria are first met for CR until the first date that progressive disease 
is objectively documented, or death due to any cause. Participants without events reported 
are censored at the last disease evaluation.
Duration of stable disease:  Stable disease is measured from the start of the treatment until 
the criteria for progression are met, taking as reference the smallest measurements recorded 
since the treatment started, including the baseline measurements. 
13.1.6 Progression-Free Survival
Overall Survival: Overall Survival (OS) is defined as the time from randomization (or 
registration) to death due to any cause, or censored at date last known alive.
Progression-Free Survival: Progression-Free Survival (PFS) is defined as the time from 
randomization (or registration) to the earlier of progression or death due to any cause. 
Participants alive without disease progression are censored at date of last disease 
evaluation.
Time to Progression: Time to Progression (TTP) is defined as the time from randomization 
(or registration) to progression, or censored at date of last disease evaluation for those 
without progression reported.
13.1.7 Response Review
Central review of restaging scans will be performed by the DF/HCC Tumor Imaging 
Metrics Core.
14. DATA REPORTING / REGULATORY REQUIREMENTS
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 8.0 
(Adverse Events: List and Reporting Requirements).
14.1 Data Reporting
14.1.1 Method
The Office of Data Quality (ODQ) will collect, manage, and perform quality checks on the 
data for this study.
14.1.2 Responsibility for Data Submission
Investigative sites within DF/HCC or DF/PCC are responsible for submitting data and/or 
data forms to the ODQ according to the schedule set by the ODQ.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
4914.2 Data Safety Monitoring
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity 
and accrual data from this study. The committee is composed of clinical specialists with experience 
in oncology and who have no direct relationship with the study. Information that raises any 
questions about participant safety will be addressed with the Overall PI and study team.
The DSMC will review each protocol up to four times a year or more often if required to review 
toxicity and accrual data. Information to be provided to the committee may include: up-to-date 
participant accrual; current dose level information; DLT information; all grade 2 or higher 
unexpected adverse events that have been reported; summary of all deaths occurring with 30 days 
of intervention for Phase I or II protocols; for gene therapy protocols, summary of all deaths while 
being treated and during active follow-up; any response information; audit results, and a summary 
provided by the study team. Other information (e.g. scans, laboratory values) will be provided 
upon request. 
14.3 Multicenter Guidelines
This protocol will adhere to the policies and requirements of the DF/HCC Multi-Center Data and 
Safety Monitoring Plan.  The specific responsibilities of the Overall PI, Coordinating Center, and 
Participating Institutions and the procedures for auditing are presented in Appendix F.
The Overall PI/Coordinating Center is responsible for distributing all IND Action Letters 
or Safety Reports to all participating institutions for submission to their individual IRBs 
for action as required.
Mechanisms will be in place to ensure quality assurance, protocol compliance, and adverse 
event reporting at each site.
Except in very unusual circumstances, each participating institution will order the study 
agent(s) directly from supplier.  A participating site may order the agent(s) only after the 
initial IRB approval for the site has been forwarded to the Coordinating Center.
15. STATISTICAL CONSIDERATIONS
15.1 Study Design/Endpoints
15.1.1 Primary Objective
This single arm, phase 2 clinical trial is testing the hypothesis that pembrolizumab has clinically 
meaningful activity in metastatic anal cancer. This multicenter trial will enroll 32 patients with 
metastatic anal cancer. 
An overall response rate of ≥20% would demonstrate clinically meaningful activity in this 
population. Based on NCCN guidelines, there are no anti-cancer regimens for patients with 
refractory, metastatic anal cancer  (Benson et al., 2012).”
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
50This study has 90% power to differentiate between an unacceptable 5% overall response rate and 
a desirable overall response rate of 20% using a one-sided binomial test with 10% type 1 error.
15.1.2 Secondary Objectives
Progression free survival and overall survival will be determined by the Kaplan-Meier method. 
Both progression free survival and overall survival will be analyzed with an intention to treat 
analysis. Overall survival will be calculated as the time from initiating treatment until death, 
progression free survival as the time until disease progression or death.
Each reported adverse event will be assigned a grade of severity in accordance with the NCI-
CTCAE version 4.0 guidelines. All adverse events will be listed. The participant incidence rate of 
treatment emergent adverse events will be summarized by treatment group and maximum severity 
(where appropriate) for all adverse events, serious adverse events, adverse events leading to 
discontinuation of protocol-specified treatment, adverse events leading to discontinuation from the 
study, and fatal adverse events. These summary tables will also be repeated for treatment-related 
adverse events.
15.1.3 Analyses of Correlative Endpoints
Subpopulations of PBMCs will be isolated, including but not limited to dendritic cells,
T cells, and B cells. Phenotype changes in these cell populations by flow cytometry will be 
determined as a function of treatment. These include regulatory and effector immune panels, naïve 
and memory CD4, CD8 and NK lymphocyte populations. Given its importance in immune 
regulation and association, we will evaluate Tie-2 expressing monocytes (TEM). 
For the analysis of cytokines, chemokines, and immune cell populations from serum or blood, data 
will be analyzed in longitudinal measurements for all patients. Serum marker levels will be 
summarized descriptively and graphically. The time course of expression levels will also be 
summarized graphically by patient and time of disease progression.
A pretreatment tumor biopsy will be utilized for analysis of tissue biomarkers. Pre-treatment 
biomarker expression, using appropriate IHC, Aperio scoring, or H-score will be reported and 
summarized using descriptive methods. We will also summarize descriptively pre-treatment 
biomarker levels according to response (PD vs. non-PD). For a sample size of 32 patients, formal 
statistical inference relating pre-treatment biomarker levels to response will be of low power and 
will be capable of detecting only a strong signal. However, we will explore the prognostic ability 
of biomarker scoring by retrospectively dividing the patient sample according to PD vs. non-PD. 
Pre-treatment immune cell infiltration and biomarker changes will be summarized graphically and 
using descriptive methods. Immune cell infiltration sub-populations will also be dichotomized into 
positive and negative at 10% (negative: < 10%, positive: ≥ 10%). 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
5116. PUBLICATION PLAN
The results should be made public within 24 months of reaching the end of the study. The end of 
the study is the time point at which the last data items are to be reported, or after the outcome data 
are sufficiently mature for analysis, as defined in the section on Sample Size, Accrual Rate and 
Study Duration. If a report is planned to be published in a peer-reviewed journal, then that initial 
release may be an abstract that meets the requirements of the International Committee of Medical 
Journal Editors. A full report of the outcomes should be made public no later than three (3) years 
after the end of the study. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
52REFERENCES
Alemany, L., M. Saunier, I. Alvarado-Cabrero, B. Quirós, J. Salmeron, H.-R. Shin, E.C. Pirog, N. 
Guimerà, G. Hernandez-Suarez, A. Felix, O. Clavero, B. Lloveras, E. Kasamatsu, M.T. Goodman, 
B.Y. Hernandez, J. Laco, L. Tinoco, D.T. Geraets, C.F. Lynch, V. Mandys, M. Poljak, R. Jach, J. 
Verge, C. Clavel, C. Ndiaye, J. Klaustermeier, A. Cubilla, X. Castellsagué, I.G. Bravo, M. Pawlita, 
W.G. Quint, N. Muñoz, F.X. Bosch, S. de Sanjosé, and H.P.V.V.S.G. on behalf of the. 2015. 
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. 
International Journal of Cancer. 136:98-107.
Benson, A.B., J.P. Arnoletti, T. Bekaii-Saab, E. Chan, Y.-J. Chen, M.A. Choti, H.S. Cooper, R.A. 
Dilawari, P.F. Engstrom, P.C. Enzinger, M.G. Fakih, J.W. Fleshman, C.S. Fuchs, J.L. Grem, L.A. 
Leong, E. Lin, K.S. May, M.F. Mulcahy, K. Murphy, E. Rohren, D.P. Ryan, L. Saltz, S. Sharma, 
D. Shibata, J.M. Skibber, W. Small, C.T. Sofocleous, A.P. Venook, C. Willett, and D.A. 
Freedman-Cass. 2012. Anal Carcinoma, Version 2.2012: Featured Updates to the NCCN 
Guidelines. Journal of the National Comprehensive Cancer Network . 10:449-454.
Brahmer, J.R., C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, E. Stankevich, A. 
Pons, T.M. Salay, T.L. McMiller, M.M. Gilson, C. Wang, M. Selby, J.M. Taube, R. Anders, L. 
Chen, A.J. Korman, D.M. Pardoll, I. Lowy, and S.L. Topalian. 2010. Phase I Study of Single-
Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical 
Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 
28:3167-3175.
Dewdney, A., and S. Rao. 2012. Metastatic Squamous Cell Carcinoma of the Anus: Time for a 
Shift in the Treatment Paradigm? ISRN Oncology. 2012:6.
Faivre, C., P. Rougier, M. Ducreux, E. Mitry, A. Lusinchi, P. Lasser, D. Elias, and F. Eschwege. 
1999. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell 
anal cancer]. Bull Cancer. 86:861-865.
Hamid, O., C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. 
Joseph, J.S. Weber, R. Dronca, T.C. Gangadhar, A. Patnaik, H. Zarour, A.M. Joshua, K. Gergich, 
J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P.C. Tumeh, B. Chmielowski, S.W. 
Ebbinghaus, X.N. Li, S.P. Kang, and A. Ribas. 2013. Safety and Tumor Responses with 
Lambrolizumab (Anti–PD-1) in Melanoma. New England Journal of Medicine . 369:134-144.
Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. 
Robert, D. Schadendorf, J.C. Hassel, W. Akerley, A.J.M. van den Eertwegh, J. Lutzky, P. Lorigan, 
J.M. Vaubel, G.P. Linette, D. Hogg, C.H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J.I. Clark, 
J.D. Wolchok, J.S. Weber, J. Tian, M.J. Yellin, G.M. Nichol, A. Hoos, and W.J. Urba. 2010. 
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal 
of Medicine. 363:711-723.
Morris, V.K., Salem, M.E., Nimeiri, H., Igbal, S., Singh, P., Ciombor, K., Polite, B., Deming, D., 
Chan, E., Wade, J.L., Xiao, L., Bekaii-Saab, T., Vence, L., Blando, J., Mahvash, A., Foo, W.C., 
Ohaji, C., Pasia, M., Bland, M., Ohinata, A., Rogers, J., Mehdizadeh, A., Banks, K., Lanman, R., 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
53Wolff, R.A., Streicher, H., Allison, J., Sharma, P., Eng, C. Nivolumab for previously treated 
unresected metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. The Lancet 
Oncology. 18:446-453. 
Ott, P.A., F.S. Hodi, and C. Robert. 2013. CTLA-4 and PD-1/PD-L1 Blockade: New 
Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical 
Cancer Research. 19:5300-5309.
Robert, C., A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, J.S. Weber, A.M. Joshua, 
W.-J. Hwu, T.C. Gangadhar, A. Patnaik, R. Dronca, H. Zarour, R.W. Joseph, P. Boasberg, B. 
Chmielowski, C. Mateus, M.A. Postow, K. Gergich, J. Elassaiss-Schaap, X.N. Li, R. Iannone, 
S.W. Ebbinghaus, S.P. Kang, and A. Daud. Anti-programmed-death-receptor-1 treatment with 
pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison 
cohort of a phase 1 trial. The Lancet . 384:1109-1117.
Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J.-F. Baurain, A. 
Testori, J.-J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W.H. Miller, P. Gascon, M. 
Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T.-T. Chen, R. Humphrey, A. Hoos, and J.D. 
Wolchok. 2011. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. 
New England Journal of Medicine . 364:2517-2526.
Serup-Hansen, E., D. Linnemann, W. Skovrider-Ruminski, E. Høgdall, P.F. Geertsen, and H. 
Havsteen. 2014. Human Papillomavirus Genotyping and p16 Expression As Prognostic Factors 
for Patients With American Joint Committee on Cancer Stages I to III Carcinoma of the Anal 
Canal. Journal of Clinical Oncology. 32:1812-1817.
Topalian, S.L., M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, J.R. 
Brahmer, D.P. Lawrence, M.B. Atkins, J.D. Powderly, P.D. Leming, E.J. Lipson, I. Puzanov, D.C. 
Smith, J.M. Taube, J.M. Wigginton, G.D. Kollia, A. Gupta, D.M. Pardoll, J.A. Sosman, and F.S. 
Hodi. 2014. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With 
Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology. 32:1020-1030.
Wolchok, J.D., A. Hoos, S. O'Day, J.S. Weber, O. Hamid, C. Lebbé, M. Maio, M. Binder, O. 
Bohnsack, G. Nichol, R. Humphrey, and F.S. Hodi. 2009. Guidelines for the Evaluation of Immune 
Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research. 
15:7412-7420.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
54APPENDIX A PERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
100Normal, no complaints, no evidence 
of disease.0Normal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction. 90Able to carry on normal activity; 
minor signs or symptoms of disease.
80Normal activity with effort; some 
signs or symptoms of disease.
1Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).70Cares for self, unable to carry on 
normal activity or to do active work.
60Requires occasional assistance, but is 
able to care for most of his/her needs.
2In bed <50% of the time.  
Ambulatory and capable of all self-
care, but unable to carry out any 
work activities.  Up and about more 
than 50% of waking hours.50Requires considerable assistance and 
frequent medical care.
40Disabled, requires special care and 
assistance.3In bed >50% of the time.  Capable 
of only limited self-care, confined 
to bed or chair more than 50% of 
waking hours.30Severely disabled, hospitalization 
indicated.  Death not imminent.
20Very sick, hospitalization indicated. 
Death not imminent.4100% bedridden.  Completely 
disabled.  Cannot carry on any self-
care.  Totally confined to bed or 
chair.10Moribund, fatal processes 
progressing rapidly.
5 Dead. 0 Dead.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
55APPENDIX B EVENTS OF CLINICAL INTEREST
1. OVERVIEW
The purpose of this document is to provide study sites with guidance on the identification and 
management of Events of Clinical Interest for the pembrolizumab (also known as MK-3475) 
program.  
Based on the literature review [1-11], and consideration of mechanism of action of pembrolizumab, 
potential immune-related adverse events (irAEs) are the primary Event of Clinical Interest (ECI). 
Immune-related AEs are adverse events associated with the treatment of patients with 
immunotherapy treatments that appear to be associated with the immune therapy’s mechanism of 
action. Based on these potential irAEs, the sponsor has defined a list of specific adverse event 
terms (ECIs) that are selected adverse experiences that must be reported to Merck within 24 
hours from the time the Investigator/physician is aware of such an occurrence, regardless of 
whether or not the investigator/physician considers the event to be related to study drug(s). In 
addition, these ECIs require additional detailed information to be collected and entered in the study 
database.  ECIs may be identified through spontaneous patient report and / or upon review of 
subject data. Table 3 provides the list of terms and reporting requirements for AEs that must be 
reported as ECIs for pembrolizumab protocols.  Of note, the requirement for reporting of ECIs 
applies to all arms, including comparators, of pembrolizumab clinical trials 
Given that our current list of events of clinical interest is not comprehensive for all potential 
immune-related events, it is possible that AEs other than those listed in this document may be 
observed in patients receiving pembrolizumab. Therefore, any Grade 3 or higher event that the 
investigator/physician considers to be immune-related should be reported as an ECI regardless of 
whether the specific event term is in Table 3 and reported to Merck within 24 hours from the 
time the Investigator/physician is aware of such an occurrence.  Adverse events that are both an 
SAE and an ECI should be reported one time as an SAE only, however the event must be 
appropriately identified as an ECI as well in in the database.  
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
56Table 3: Events of Clinical Interest
Pneumonitis (reported as ECI if  ≥ Grade 2)
Acute interstitial pneumonitis Interstitial lung disease Pneumonitis
Colitis (reported as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Intestinal Obstruction Colitis Colitis microscopic
Enterocolitis Enterocolitis hemorrhagic Gastrointestinal perforation
Necrotizing colitis Diarrhea
Endocrine (reported as ECI if  ≥ Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic steroids to treat 
the AE)
Adrenal Insufficiency Hyperthyroidism Hypophysitis
Hypopituitarism Hypothyroidism Thyroid disorder
Thyroiditis Hyperglycemia, if ≥Grade 3 and associated with ketosis or metabolic acidosis (DKA)
Endocrine (reported as ECI)
Type 1 diabetes mellitus (if new onset)
Hematologic (reported as ECI if  ≥ Grade 3 or any grade resulting in dose modification or use of systemic steroids to treat the 
AE)
Autoimmune hemolytic anemia Aplastic anemia Thrombotic Thrombocytopenic Purpura 
(TTP)
Idiopathic (or immune) Thrombocytopenia 
Purpura  (ITP)Disseminated Intravascular Coagulation 
(DIC)Haemolytic Uraemic Syndrome (HUS)
Any Grade 4 anemia regardless of underlying mechanism
Hepatic (reported as ECI if  ≥ Grade 2, or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Hepatitis Autoimmune hepatitis Transaminase elevations (ALT and/or AST)
Infusion Reactions (reported as ECI for any grade)
Allergic reaction Anaphylaxis Cytokine release syndrome
Serum sickness Infusion reactions Infusion-like reactions
Neurologic (reported as ECI for any grade)
Autoimmune neuropathy Guillain-Barre syndrome Demyelinating polyneuropathy
Myasthenic syndrome
Ocular (report as ECI if  ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Uveitis Iritis
Renal (reported as ECI if  ≥ Grade 2) 
Nephritis Nephritis autoimmune Renal Failure
Renal failure acuteCreatinine elevations (report as ECI if ≥Grade 3 or any grade resulting in dose 
modification or use of systemic steroids to treat the AE)
Skin (reported as ECI for any grade)
Dermatitis exfoliative Erythema multiforme Stevens-Johnson syndrome
Toxic epidermal necrolysis
Skin (reported as ECI if ≥ Grade 3)
Pruritus Rash Rash generalized
Rash maculo-papular
Any rash considered clinically significant in the physician’s judgment 
Other (reported as ECI for any grade)
Myocarditis Pancreatitis Pericarditis
Any other Grade 3 event which is considered immune-related by the physician
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
57Each of the events above is described within this guidance document, along with site requirements 
for reporting these events to the Sponsor.  The information collected should be entered into the 
narrative field(s) of the Adverse Event module in the database (please note, if narrative entry into 
the database is not available, please use the narrative text box on the 1727/AER Form).  If 
additional Medical History or Concomitant Medications are reported, the Medical History and 
Concomitant Medication modules in the database must be updated.  
In addition, the guidelines include recommendations on the management of these ECIs. These 
guidelines are intended to be applied when the physician determines the events to be related to 
pembrolizumab. Note: if after the evaluation the event is determined not to be related, the physician 
is instructed to follow the ECI reporting guidance but does not need to follow the treatment 
guidance (below). Therefore, these recommendations should be seen as guidelines and the treating 
physician should exercise individual clinical judgment based on the patient.  For any question of 
dose modification or other treatment options, the specific language in the protocol should be 
followed.  Any questions pertaining to the collection of this information or management of ECIs 
should be directed to your local Sponsor contact. 
Dose Modification/Discontinuation
The treatment guidance provides specific direction when to hold and/or discontinue 
pembrolizumab for each immune related adverse event.  Of note, when the guidance states to 
“discontinue” pembrolizumab this is the permanent discontinuation of treatment with 
pembrolizumab. “Hold” means to stop treating with pembrolizumab but resumption of treatment 
may be considered assuming the patient meets the criteria for resumption of treatment.  
2. ECI REPORTING GUIDELINES
ECIs are selected non-serious and serious adverse experiences that must be reported to Merck 
within 24 hours regardless of attribution to study treatment.  The AEs listed in this document and 
any event that meets the ECI criteria (as noted) in Table 1 or in the respective protocol (event term 
and Grade) must be reported regardless of physician-determined causality with study medication 
and whether or not considered immune-related by the physician (unless otherwise specified).   
Physicians/study coordinators/designated site personnel are required to record these experiences 
as ECIs on the Adverse Experience electronic Case Report Forms (eCRFs) (or on paper) and to 
provide supplemental information (such as medical history, concomitant medications, 
investigations, etc.) about the event.  
–
– Please refer to protocol for details on reporting timelines and reporting of Overdose and 
Drug Induced Liver Injury (DILI).  Refer to Appendix B, Section 3.5.
3. ECI CATEGORIES AND TERMS
This section describes the ECI categories and outlines subject management guidelines when an 
ECI is reported.     
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
583.1 Pneumonitis
The following AE terms, if considered ≥ Grade 2, are considered ECIs and should be reported to 
the Sponsor within 24 hours of the event:
– Pneumonitis
– Interstitial lung disease
– Acute interstitial pneumonitis 
If symptoms indicate possible new or worsening cardiac abnormalities additional testing and/or a 
cardiology consultation should be considered. 
All attempts should be made to rule out other causes such as metastatic disease, bacterial or viral 
infection.  It is important that patients with a suspected diagnosis of pneumonitis be managed 
as per the guidance below until treatment-related pneumonitis is excluded.  Treatment of 
both a potential infectious etiology and pneumonitis in parallel may be warranted.  
Management of the treatment of suspected pneumonitis with steroid treatment should not 
be delayed for a therapeutic trial of antibiotics.  If an alternative diagnosis is established, the 
patient does not require management as below; however the AE should be reported regardless of 
etiology.
Course of Action
Grade 2 events:
– Report as ECI
– Hold pembrolizumab.
– Consider pulmonary consultation with bronchoscopy and biopsy/BAL.
– Consider ID consult
– Conduct an in person evaluation approximately twice per week
– Consider frequent Chest X-ray as part of monitoring
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg/day prednisone or equivalent.  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.   
– Second episode of pneumonitis – discontinue pembrolizumab if upon re-challenge the 
patient develops a second episode of Grade 2 or higher pneumonitis.
Grade 3 and 4 events:
– Report as ECI
– Discontinue pembrolizumab.
– Hospitalize patient
– Bronchoscopy with biopsy and/or BAL is recommended.
– Immediately treat with intravenous steroids (methylprednisolone 125 mg IV). When 
symptoms improve to Grade 1 or less, a high dose oral steroid (prednisone 1 to 2 mg/kg 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
59once per day or dexamethasone 4 mg every 4 hours) taper should be started and continued 
over no less than 4 weeks.
– If IV steroids followed by high dose oral steroids does not reduce initial symptoms within 
48 to 72 hours, treat with additional anti-inflammatory measures. Discontinue additional 
anti-inflammatory measures upon symptom relief and initiate a prolonged steroid taper 
over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering of 
steroids starting at a higher dose of 80 or 100 mg followed by a more prolonged taper and 
administer additional anti-inflammatory measures, as needed
– Add prophylactic antibiotics for opportunistic infections.
3.2 Colitis
The following AE terms, if considered ≥ Grade 2 or resulting in dose modification or use of 
systemic steroids to treat the AE, are considered ECIs and should be reported to the Sponsor within 
24 hours of the event: 
– Colitis 
– Colitis microscopic
– Enterocolitis
– Enterocolitis hemorrhagic 
– Gastrointestinal perforation
– Intestinal obstruction 
– Necrotizing colitis
– Diarrhea
All attempts should be made to rule out other causes such as metastatic disease, bacterial or 
parasitic infection, viral gastroenteritis, or the first manifestation of an inflammatory bowel disease 
by examination for stool leukocytes, stool cultures, a Clostridium difficile titer and endoscopy.   
However, the AE should be reported regardless of etiology.
Course of Action
Grade 2 Diarrhea/Colitis (4-6 stools/day over baseline, dehydration requiring IV fluids < 24 hours, 
abdominal pain, mucus or blood in stool):  
– Report as ECI
– Hold pembrolizumab. 
– Symptomatic Treatment
– For Grade 2 diarrhea that persists for greater than 3 days, and for diarrhea with blood and/or 
mucus, 
oConsider GI consultation and endoscopy to confirm or rule out colitis 
oAdminister oral corticosteroids (prednisone 1-2 mg/kg QD or equivalent)
– When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.   
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
– If symptoms worsen or persist > 3 days treat as Grade 3
Grade 3 Diarrhea/Colitis (or Grade 2 diarrhea that persists for > 1 week):
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
60– Report as ECI
– Hold pembrolizumab. 
– Rule out bowel perforation.  Imaging with plain films or CT can be useful.
– Recommend consultation with Gastroenterologist and confirmation biopsy with endoscopy.
– Treat with intravenous steroids (methylprednisolone 125 mg) followed by high dose oral 
steroids (prednisone 1 to 2 mg/kg once per day or dexamethasone 4 mg every 4 hours)  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.  Taper over 6 to 8 weeks in patients with diffuse and severe 
ulceration and/or bleeding.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
– If IV steroids followed by high dose oral steroids does not reduce initial symptoms within 
48 to 72 hours, consider treatment with additional anti-inflammatory measures as described 
in the literature [5]. Discontinue additional anti-inflammatory measures upon symptom 
relief and initiate a prolonged steroid taper over 45 to 60 days. If symptoms worsen during 
steroid reduction, initiate a retapering of steroids starting at a higher dose of 80 or 100 mg 
followed by a more prolonged taper and administer additional anti-inflammatory measures 
as needed. 
Grade 4 events: 
– Report as ECI
– Permanently discontinue pembrolizumab.
– Manage as per Grade 3.
3.3 Endocrine
The following AE terms, if considered ≥ Grade 3 or if ≥ Grade 2 and require 
holding/discontinuation/ modification of pembrolizumab dosing, are considered ECIs and should 
be reported to the Sponsor within 24 hours of the event:  
– Adrenal insufficiency
– Hyperthyroidism
– Hypophysitis
– Hypopituitarism 
– Hypothyroidism
– Thyroid disorder 
– Thyroiditis 
All attempts should be made to rule out other causes such as brain metastases, sepsis and/or 
infection.  However, the AE should be reported regardless of etiology.
Hypophysitis or other symptomatic endocrinopathy other than hypo- or hyperthyroidism
Grade 2-4 events:
– Report as ECI if appropriate
– Hold pembrolizumab
– Rule out infection and sepsis with appropriate cultures and imaging.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
61– Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
– Pituitary gland imaging should be considered (MRIs with gadolinium and selective cuts of 
the pituitary can show enlargement or heterogeneity and confirm the diagnosis).
– Treat with prednisone 40 mg p.o. or equivalent per day.  When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4 weeks.  
Replacement of appropriate hormones may be required as the steroid dose is tapered. 
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. 
– Hypophysitis with clinically significant adrenal insufficiency and hypotension, 
dehydration, and electrolyte abnormalities (such as hyponatremia and hyperkalemia) 
constitutes adrenal crisis.
– Consultation with an endocrinologist may be considered.
Hyperthyroidism and Hypothyroidism
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated 
based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
Grade 2 hyperthyroidism, Grade 2-4 hypothyroidism events:
– Report as ECI if appropriate (see Table 1)
– Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
– Thyroid hormone and/or steroid replacement therapy to manage adrenal insufficiency.
– Therapy with pembrolizumab can be continued while treatment for the thyroid disorder is 
instituted. 
– In hyperthyroidism, non-selective beta-blockers (e.g. propranolol) are suggested as initial 
therapy. 
– In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothyroinine, is indicated per standard of care. 
– Consultation with an endocrinologist may be considered.
Grade 3 hyperthyroidism events:
– Report as ECI
– Hold pembrolizumab. 
– Rule out infection and sepsis with appropriate cultures and imaging.
– Treat with an initial dose of methylprednisolone 1 to 2 mg/kg intravenously followed by 
oral prednisone 1 to 2 mg/kg per day.  When symptoms improve to Grade 1 or less, steroid 
taper should be started and continued over no less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered. 
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 hyperthyroidism events:
– Report as ECI
– Discontinue pembrolizumab. 
– Manage as per Grade 3
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
62Type 1 diabetes mellitus (if new onset) and ≥ Grade 3 Hyperglycemia
The following AE terms are considered ECIs and should be reported to the Sponsor within 24 
hours of the event:
– Type I diabetes mellitus (T1DM), if new onset, including diabetic ketoacidosis (DKA) 
– Grade 3 or higher hyperglycemia, if associated with ketosis (ketonuria) or metabolic 
acidosis (DKA).
Immune-mediated diabetes may present as new onset of Type 1 diabetes or an abrupt worsening 
of pre-existing diabetes associated with laboratorial evidence of beta cell failure. All attempts 
should be made to rule out other causes such as type 2 diabetes mellitus (T2DM), T2DM 
decompensation, steroid-induced diabetes, physiologic stress-induced diabetes, or poorly 
controlled pre-existing diabetes (either T1DM or T2DM), but events meeting the above criteria 
should be reported as ECIs regardless of etiology. The patients may present with hyperglycemia 
(abrupt onset or abrupt decompensation) with clinical evidence of diabetic ketoacidosis or 
laboratory evidence of insulin deficiency, such as ketonuria, laboratory evidence of metabolic 
acidosis, or low or undetected c-peptide.
Course of Action
T1DM should be immediately treated with insulin.
T1DM or Grade 3-4 Hyperglycemia events:
- Report as ECI if appropriate (see Table 1)
- Hold pembrolizumab for new onset Type 1 diabetes mellitus or Grade 3-4 hyperglycemia 
associated with evidence of beta cell failure, and resume pembrolizumab when patients are 
clinically and metabolically stable. 
- Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 
3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
- Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated 
hemoglobin, and C-peptide. 
- Consultation with an Endocrinologist is recommended.
- Consider local testing for islet cell antibodies and antibodies to GAD, IA-2, ZnT8, and 
insulin may be obtained. 
3.4 Hematologic
The following AE term, if considered Grade ≥3 or requiring dose modification or use of systemic 
steroids to treat the AE, are considered an ECI and should be reported to the Sponsor within 24 
hours of the event:
– Autoimmune hemolytic anemia
– Aplastic anemia
– Disseminated Intravascular Coagulation (DIC)
– Haemolytic Uraemic Syndrome (HUS)
– Idiopathic (or immune) Thrombocytopenia Purpura (ITP)
– Thrombotic Thrombocytopenic Purpura (TTP)
– Any Grade 4 anemia regardless of underlying mechanism
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
63All attempts should be made to rule out other causes such as metastases, sepsis and/or infection.   
Relevant diagnostic studies such as peripheral blood smear, reticulocyte count, LDH, haptoglobin, 
bone marrow biopsy or Coomb’s test, etc., should be considered to confirm the diagnosis. However, 
the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
– Report as ECI
– Hold pembrolizumab
– Prednisone 1-2 mg/kg daily may be indicated
– Consider Hematology consultation.
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 events:
– Report as ECI
– Hematology consultation. 
– Hold pembrolizumab   Discontinuation should be considered as per specific protocol 
guidance.
– Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg p.o. (or equivalent) as 
appropriate
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
– Report as ECI
– Hematology consultation
– Discontinue pembrolizumab for all solid tumor indications
– Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg p.o. (or equivalent) as 
appropriate
3.5 Hepatic
The following AE terms, if considered ≥ Grade 2 or greater (or any grade with dose modification 
or use of systemic steroids to treat the AE), are considered ECIs and should be reported to the 
Sponsor within 24 hours of the event:  
– Autoimmune hepatitis 
– Hepatitis 
– Transaminase elevations
All attempts should be made to rule out other causes such as metastatic disease, infection or other 
hepatic diseases. However, the AE should be reported regardless of etiology.
Drug Induced Liver Injury (DILI)
In addition, the event must be reported as a Drug Induced Liver Injury (DILI) ECI, if the patient 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
64meets the laboratory criteria for potential DILI defined as: 
An elevated alanine transaminase (ALT) or aspartate transaminase (AST) lab value that is 
greater than or equal to three times (3X) the upper limit of normal (ULN) and 
An elevated total bilirubin lab value that is greater than or equal to two times (2X) ULN 
and
At the same time, an alkaline phosphatase (ALP) lab value that is less than 2X ULN, 
As a result of within-protocol-specific testing or unscheduled testing.
Note that any hepatic immune ECI meeting DILI criteria should only be reported once as a DILI 
event.  
Course of Action
Grade 2 events:
– Report as ECI
– Hold pembrolizumab when AST or ALT >3.0 to 5.0 times ULN and/or total bilirubin >1.5 
to 3.0 times ULN.
– Monitor liver function tests more frequently until returned to baseline values (consider 
weekly).
oTreat with 0.5-1 mg/kg/day methylprednisolone or oral equivalent and when LFT 
returns to grade 1 or baseline, taper steroids over at least 1 month, consider 
prophylactic antibiotics for opportunistic infections, and resume pembrolizumab 
per protocol 
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
– Permanently discontinue pembrolizumab for patients with liver metastasis who begin 
treatment with Grade 2 elevation of AST or ALT, and AST or ALT increases ≥50% relative 
to baseline and lasts ≥1 week.
Grade 3 events:
– Report as ECI
– Discontinue pembrolizumab when AST or ALT >5.0 times ULN and/or total bilirubin >3.0 
times ULN.  
– Consider appropriate consultation and liver biopsy to establish etiology of hepatic injury, 
if necessary
– Treat with high-dose intravenous glucocorticosteroids for 24 to 48 hours.  When symptoms 
improve to Grade 1 or less, a steroid taper with dexamethasone 4 mg every 4 hours or 
prednisone at 1 to 2 mg/kg should be started and continued over no less than 4 weeks. 
– If serum transaminase levels do not decrease 48 hours after initiation of systemic steroids, 
oral mycophenolate mofetil 500 mg every 12 hours may be given. Infliximab is not 
recommended due to its potential for hepatotoxicity.
– Several courses of steroid tapering may be necessary as symptoms may worsen when the 
steroid dose is decreased.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
65Grade 4 events: 
– Report as ECI
– Permanently discontinue pembrolizumab
– Manage patient as per Grade 3 above
3.6 Neurologic
The following AE terms, regardless of grade, are considered ECIs and should be reported to the 
Sponsor within 24 hours of the event:
– Autoimmune neuropathy
– Demyelinating polyneuropathy
– Guillain-Barre syndrome
– Myasthenic syndrome
All attempts should be made to rule out other causes such as metastatic disease, other medications 
or infectious causes. However, the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
– Report as ECI
– Moderate (Grade 2) – consider withholding pembrolizumab. 
– Consider treatment with prednisone 1-2 mg/kg p.o. daily as appropriate
– Consider Neurology consultation. Consider biopsy for confirmation of diagnosis.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 and 4 events:
– Report as ECI
– Discontinue pembrolizumab
– Obtain neurology consultation.  Consider biopsy for confirmation of diagnosis
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent once 
per day. If condition worsens, consider IVIG or other immunosuppressive therapies as per 
local guidelines
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no 
less than 4 weeks.
3.7 Ocular
The following AE terms, if considered Grade ≥2 or requiring dose modification or use of systemic 
steroids to treat the AE, is considered an ECI and should be reported to the Sponsor within 24 
hours of the event:
– Uveitis
– Iritis 
All attempts should be made to rule out other causes such as metastatic disease, infection or other 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
66ocular disease (e.g. glaucoma or cataracts). However, the AE should be reported regardless of 
etiology.
Course of Action
Grade 2 events: 
– Evaluation by an ophthalmologist is strongly recommended.
– Treat with topical steroids such as 1% prednisolone acetate suspension and iridocyclitics.
– Discontinue pembrolizumab as per protocol if symptoms persist despite treatment with 
topical immunosuppressive therapy.
Grade 3 events:
– Evaluation by an ophthalmologist is strongly recommended 
– Hold pembrolizumab and consider permanent discontinuation as per specific protocol 
guidance.
– Treat with systemic corticosteroids such as prednisone at a dose of 1 to 2 mg/kg per day.  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events: 
– Evaluation by an ophthalmologist is strongly recommended 
– Permanently discontinue pembrolizumab.
– Treat with corticosteroids as per Grade 3 above
3.8 Renal
The following AEs if ≥ Grade 2 are considered ECIs and should be reported to the Sponsor within 
24 hours of the event:
– Nephritis
– Nephritis autoimmune
– Renal failure
– Renal failure acute
Creatinine elevations ≥ Grade 3 or any grade with dose modification or use of systemic steroids to 
treat the AE.
All attempts should be made to rule out other causes such as obstructive uropathy, progression of 
disease, or injury due to other chemotherapy agents.  A renal consultation is recommended. 
However, the AE should be reported regardless of etiology.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
67Course of Action
Grade 2 events:
– Hold pembrolizumab
– Treatment with prednisone 1-2 mg/kg p.o. daily.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3-4 events: 
– Discontinue pembrolizumab
– Renal consultation with consideration of ultrasound and/or biopsy as appropriate
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone IV or equivalent 
once per day.  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no 
less than 4 weeks.  
3.9 Skin
Rash and Pruritus
The following AEs should be considered as ECIs, if ≥ Grade 3 and should be reported to the 
Sponsor within 24 hours of the event: 
– Pruritus
– Rash
– Rash generalized
– Rash maculo-papular
– In addition to CTCAE Grade 3 rash, any rash that is considered clinically significant, in 
the physician's judgment, should be treated as an ECI. Clinical significance is left to the 
physician to determine, and could possibly include rashes such as the following: 
orash with a duration >2 weeks; OR 
orash that is >10% body surface area; OR 
orash that causes significant discomfort not relieved by topical medication or temporary 
cessation of study drug.
Other Skin ECIs
The following AEs should always  be reported as ECIs, regardless of grade, and should be reported 
to the Sponsor within 24 hours of the event: 
– Dermatitis exfoliative
– Erythema multiforme
– Steven’s Johnson syndrome
– Toxic epidermal necrolysis
Please note, the AE should be reported regardless of etiology.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
68Course of Action
Grade 2 events:
– Symptomatic treatment should be given such as topical glucocorticosteroids (e.g., 
betamethasone 0.1% cream or hydrocortisone 1%) or urea-containing creams in 
combination with oral anti-pruritics (e.g., diphenhydramine HCl or hydroxyzine HCl). 
– Treatment with oral steroids is at physician’s discretion for Grade 2 events.
Grade 3 events:
– Hold pembrolizumab.
– Consider Dermatology Consultation and biopsy for confirmation of diagnosis.
– Treatment with oral steroids is recommended, starting with 1 mg/kg prednisone or 
equivalent once per day or dexamethasone 4 mg four times orally daily.  When symptoms 
improve to Grade 1 or less, steroid taper should be started and continued over no less than 
4 weeks.
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
– Permanently discontinue pembrolizumab.
– Dermatology consultation and consideration of biopsy and clinical dermatology 
photograph.
– Initiate steroids at 1 to 2 mg/kg prednisone or equivalent.  When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.
3.9.1. Immediate Evaluation for Potential Skin ECIs
A. Photographs : 
Every attempt should be made to get a photograph of the actual ECI skin lesion or rash as soon as 
possible. Obtain appropriate consent for subject photographs if a consent form addendum is 
required by your IRB/ERC. 
– Take digital photographs of: 
othe head (to assess mucosal or eye involvement), 
othe trunk and extremities, and 
oa close-up of the skin lesion/rash. 
– If possible, a ruler should be placed alongside the site of a skin occurrence as a fixed marker 
of distance. 
– The time/date stamp should be set in the 'ON' position for documentation purposes. 
– Photographs should be stored with the subject’s study records. 
– The Sponsor may request copies of photographs. The local study contact (e.g., CRA) will 
provide guidance to the site, if needed. 
B. Past Medical History: 
Collect past medical history relevant to the event, using the questions in Appendix C (Past Medical 
History Related to Dermatologic Event) as a guide. Any preexisting conditions not previously 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
69reported (e.g., drug allergy) should be entered into the Medical History eCRF. 
C. Presentation of the Event: 
Collect information on clinical presentation and potential contributing factors using the questions 
in Appendix D (Presentation of the Dermatologic Event) as a guide. This information should be 
summarized and entered in narrative format in the AE eCRF. Please use the available free-text 
fields, such as Signs and Symptoms. Note pertinent negatives where applicable to reflect that the 
information was collected. Any treatments administered should be entered on the Concomitant 
Medication eCRF. 
D. Vitals Signs and Standard Laboratory Tests: 
Measure vital signs (pulse, sitting BP, oral temperature, and respiratory rate) and record on the 
Vital Signs eCRF.  Perform standard laboratory tests (CBC with manual differential and serum 
chemistry panel, including LFTs). 
E. Focused Skin Examination: 
Perform a focused skin examination using the questions in Appendix E (Focused Skin 
Examination) as a guide. Information should be summarized and entered on the Adverse 
Experience eCRF as part of the narrative. 
F. Dermatology Consult 
Refer the subject to a dermatologist as soon as possible. 
– For a “severe rash”, the subject must be seen within 1-2 days of reporting the event. 
– For clinically significant rash, the subject should be seen within 3-5 days. 
The dermatologist should submit a biopsy sample to a certified dermatopathology laboratory or to 
a pathologist experienced in reviewing skin specimens. 
The site should provide the dermatologist with all relevant case history, including copies of clinical 
photographs and laboratory test results. 
3.10 Other
The following AEs, regardless of grade, are considered ECIs and should be reported to the Sponsor 
within 24 hours of the event:
– Myocarditis
– Pericarditis
– Pancreatitis
– Any additional Grade 3 or higher event which the physician considers to be immune related
All attempts should be made to rule out other causes.  Therapeutic specialists should be consulted 
as appropriate. However, the AE should be reported regardless of etiology.
Course of Action
Grade 2 events or Grade 1 events that do not improve with symptomatic treatment:
– Withhold pembrolizumab.  
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
70– Systemic corticosteroids may be indicated. 
– Consider biopsy for confirmation of diagnosis.
– If pembrolizumab held and corticosteroid required, manage as per grade 3 below.
Grade 3 events:
– Hold pembrolizumab
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent once 
per day.  
– When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.  
– Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. Otherwise, pembrolizumab treatment 
may be restarted and the dose modified as specified in the protocol
Grade 4 events:
– Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent once 
per day.  
– Discontinue pembrolizumab 
3.11 Infusion Reactions
The following AE terms, regardless of grade, are considered ECIs and should be reported to the 
Sponsor within 24 hours of the event:
– Allergic reaction
– Anaphylaxis
– Cytokine release syndrome
– Serum sickness
– Infusion reactions
– Infusion-like reactions
Please note, the AE should be reported regardless of etiology.
Course of Action
Refer to infusion reaction table in the protocol and below.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
71Infusion Reactions
NCI CTCAE Grade Treatment Premedication at subsequent 
dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the investigator.None
Grade 2
Requires infusion interruption but 
responds promptly to 
symptomatic treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV fluids); prophylactic 
medications indicated for < =24 
hrsStop Infusion.
Additional appropriate medical therapy 
may include but is not limited to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the investigator.
If symptoms resolve within one hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion 
rate (e.g. from 100 mL/hr to 50 mL/hr).  
Otherwise dosing will be held until 
symptoms resolve and the subject should be 
premedicated for the next scheduled dose.
Subjects who develop Grade 2 toxicity 
despite adequate premedication should 
be permanently discontinued from 
further trial treatment administration.Subject may be premedicated 
1.5h (± 30 minutes) prior to 
infusion of pembrolizumab 
with:
Diphenhydramine 50 mg p.o. 
(or equivalent dose of 
antihistamine).
Acetaminophen 500-1000 mg 
p.o. (or equivalent dose of 
antipyretic).
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical therapy 
may include but is not limited to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Epinephrine
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the investigator.
Hospitalization may be indicated.
Subject is permanently discontinued 
from further trial treatment 
administration.No subsequent dosing
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
For Further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at 
http://ctep.cancer.gov
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
723.12 Follow-up to Resolution 
Subjects should be followed to resolution. The Adverse Experience eCRF should be updated with 
information regarding duration and clinical course of the event. Information obtained from the 
consulting specialist, including diagnosis, should be recorded in the appropriate AE fields. Free-
text fields should be used to record narrative information: 
– Clinical course of the event 
– Course of treatment 
– Evidence supporting recovery 
– Follow-up to the clinical course 
Any treatments administered for the event should also be entered in the Concomitant Medication 
eCRF. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
734. REFERENCES
1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.  Nature Reviews 
Cancer 2012; 12:252-264.
2. Weber JS Practical Management of Immune-Related Adverse Events from Immune 
Checkpoint Protein Antibodies for the Oncologist. American Society of Clinical Oncology 
2012; 1092-9118/10/1-10.
3. Weber JS, Ka¨hler KC, and Hauschild A. Management of Immune-Related Adverse Events 
and Kinetics of Response With Ipilimumab. J Clin Oncol 30. 2012. 
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.41.6750.
4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved Survival with 
Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363:711-723, 2010.
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012; 
366:2443-2454.
6. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, et al. Safety and Activity of Anti–PD-L1 
Antibody in Patients with Advanced Cancer.  N Engl J Med 2012; 366:2455-2465.
7. Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, 
phase II study comparing the tolerability and efficacy of ipilimumab administered with or 
without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin 
Cancer Res 15:5591-5598, 2009.
8. Lemech C and Arkenau HT. Novel Treatments for Metastatic Cutaneous Melanoma and the 
Management of Emergent Toxicities. Clinical Medicine Insights: Oncology 2012:6 53–66.
9. Phan GQ, Weber JS, and Sondak VK.  CTLA-4 Blockade with Monoclonal Antibodies in 
Patients with Metastatic Cancer: Surgical Issues. Annals of Surgical Oncology 15(11):3014–
3021.
10. Bristol-Myers Squibb: YERVOY (ipilimumab): Serious and fatal immune-mediated adverse 
reactions—YERVOY Risk Evaluation and Mitigation Strategy (REMS). 
http://www.yervoy.com/hcp/rems.aspx
11. Bristol-Myers Squibb: YERVOY (ipilimumab) prescribing information revised March 2011. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
745. EVENTS OF CLINICAL INTEREST (ECI) – REFERENCE TABLE
Pneumonitis (reported as ECI if  ≥ Grade 2)
Acute interstitial pneumonitis Interstitial lung disease Pneumonitis
Colitis (reported as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Intestinal Obstruction Colitis Colitis microscopic
Enterocolitis Enterocolitis hemorrhagic Gastrointestinal perforation
Necrotizing colitis Diarrhea
Endocrine (reported as ECI if  ≥ Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic steroids to treat 
the AE)
Adrenal Insufficiency Hyperthyroidism Hypophysitis
Hypopituitarism Hypothyroidism Thyroid disorder
Thyroiditis Hyperglycemia, if ≥Grade 3 and associated with ketosis or metabolic acidosis (DKA)
Endocrine (reported as ECI)
Type 1 diabetes mellitus (if new onset)
Hematologic (reported as ECI if  ≥ Grade 3 or any grade resulting in dose modification or use of systemic steroids to treat the 
AE)
Autoimmune hemolytic anemia Aplastic anemia Thrombotic Thrombocytopenic Purpura 
(TTP)
Idiopathic (or immune) Thrombocytopenia 
Purpura  (ITP)Disseminated Intravascular Coagulation 
(DIC)Haemolytic Uraemic Syndrome (HUS)
Any Grade 4 anemia regardless of underlying mechanism
Hepatic (reported as ECI if  ≥ Grade 2, or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Hepatitis Autoimmune hepatitis Transaminase elevations (ALT and/or AST)
Infusion Reactions (reported as ECI for any grade)
Allergic reaction Anaphylaxis Cytokine release syndrome
Serum sickness Infusion reactions Infusion-like reactions
Neurologic (reported as ECI for any grade)
Autoimmune neuropathy Guillain-Barre syndrome Demyelinating polyneuropathy
Myasthenic syndrome
Ocular (report as ECI if  ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat the AE)
Uveitis Iritis
Renal (reported as ECI if  ≥ Grade 2) 
Nephritis Nephritis autoimmune Renal Failure
Renal failure acuteCreatinine elevations (report as ECI if ≥Grade 3 or any grade resulting in dose 
modification or use of systemic steroids to treat the AE)
Skin (reported as ECI for any grade)
Dermatitis exfoliative Erythema multiforme Stevens-Johnson syndrome
Toxic epidermal necrolysis
Skin (reported as ECI if ≥ Grade 3)
Pruritus Rash Rash generalized
Rash maculo-papular
Any rash considered clinically significant in the physician’s judgment 
Other (reported as ECI for any grade)
Myocarditis Pancreatitis Pericarditis
Any other Grade 3 event which is considered immune-related by the physician
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
75APPENDIX C – PAST MEDICAL HISTORY RELATED TO DERMATOLOGIC EVENT
Past Medical History: 
Any preexisting conditions not previously reported (e.g., drug allergy) should be entered into the Medical 
History eCRF. 
1. Does the subject have any allergies? □ Yes □ No 
If yes, please obtain the following information: 
a. Any allergy to drugs (including topical or ophthalmic drugs)? □ Yes □ No 
List the drug name(s) and describe the type of allergic response (e.g. rash, anaphylaxis, etc): 
_____________________________________________________________ 
_____________________________________________________________ 
b. Any allergy to external agents, such as laundry detergents, soaps, poison ivy, nickel, etc.?
□ Yes □ No 
Describe the agent and type of allergic response: _____________________ 
_____________________________________________________________ 
c. Any allergy to food? □ Yes □ No 
Describe the food and type of allergic response: _____________________ 
____________________________________________________________ 
d. Any allergy to animals, insects? □ Yes □ No 
Describe the allergen and type of allergic response: ___________________ 
____________________________________________________________ 
e. Any other allergy? □ Yes □ No 
Describe the allergen and type of allergic response: __________________
___________________________________________________________ 
2. Does the subject have any other history of skin reactions, skin eruptions, or rashes?
□ Yes □ No 
If so what kind? ______________________________________________ 
3. Has the subject ever been treated for a skin condition?
□ Yes □ No 
If so what kind? ______________________________________________ 
4. Is the current finding similar to a past experience? □ Yes □ No 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
76APPENDIX D – PRESENTATION OF THE DERMATOLOGIC EVENT
Presentation of the event: 
Collect information on clinical presentation and potential contributing factors. Key information should be 
summarized and entered on the Adverse Experience eCRF. Any treatments administered should be entered 
on the Concomitant Medication eCRF. 
1. What is the onset time of the skin reaction, skin eruption, or rash relative to dose of study drug?
             ________________________________________________________________ 
2. Has the subject contacted any known allergens? □ Yes □ No 
If so what kind? __________________________________________________
3. Has the subject contacted new, special, or unusual substances (e.g., new laundry detergents, soap, 
personal care product, poison ivy, etc.)? □ Yes □ No 
If so what kind? _________________________________________________ 
4. Has the subject taken any other medication (over the counter, prescription, vitamins, and supplement)?  
□ Yes □ No 
If so what kind? _________________________________________________ 
5. Has the subject consumed unaccustomed, special or unusual foods? □ Yes □ No 
If so what kind? _________________________________________________ 
6. Does the subject have or had in the last few days any illness? □ Yes □ No 
If so what kind? __________________________________________________ 
7. Has the subject come into contact with any family or house members who are ill?
□Yes □ No 
If so who and what? _____________________________________________ 
8. Has the subject recently been near children who have a skin reaction, skin eruption, or rash (e.g. 
Molluscum Contagiosum)? □ Yes □ No 
9. Has the subject had recent sun exposure? □ Yes □ No 
10. For the current rash, have there been any systemic clinical signs? □ Yes □ No 
If so what kind? ________________________________________________ 
i. Anaphylaxis? □ Yes □ No 
ii. Signs of hypotension? □ Yes □ No 
iii. Signs of dyspnea? □ Yes □ No 
iv. Fever, night sweats, chills? □ Yes □ No 
11. For the current rash, has the subject needed subcutaneous epinephrine or other systemic catecholamine 
therapy? □ Yes □ No 
If so what kind? ________________________________________________ 
12. For the current rash, has the subject used any other medication, such as inhaled bronchodilators, 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
77antihistaminic medication, topical corticosteroid, and/or systemic corticosteroid?
□ Yes □ No 
List medication(s) and dose(s): _________________________________________ 
___________________________________________________________________
13. Is the rash pruritic (itchy)? □ Yes □ No 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
78APPENDIX E – FOCUSED SKIN EXAMINATION
Focused Skin Examination: 
Key information should be summarized and entered on the Adverse Experience eCRF. 
Primary Skin Lesions Description 
Color: _______________________________________________________ 
General description: 
______________________________________________________________ 
______________________________________________________________ 
Describe the distribution of skin reaction, skin eruption, or rash on the body: 
______________________________________________________________ 
______________________________________________________________ 
Is skin reaction, skin eruption, or rash resolving or continuing to spread? 
______________________________________________________________ 
______________________________________________________________ 
Any associated signs on physical examination? 
______________________________________________________________
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
79APPENDIX F – DF/HCC MULTI-CENTER DATA AND SAFETY MONITORING PLAN
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
8016.1 3.1 DRUG PRODUCT 
Pembrolizumab (MK-3475) Solution for Infusion, 100 mg/ 4 mL vial
Pembrolizumab (MK-3475) Solution for Infusion is a sterile, non-pyrogenic aqueous solution 
supplied in single-use Type I glass vial containing 100 mg/4 mL of pembrolizumab (MK-
3475). The product is preservative-free, latex free solution which is essentially free of 
extraneous particulates.
Cap color of MK-3475 (Pembrolizumab) 100 mg vials:
Both red, salmon, and blue color caps may be used. Though the cap color may 
be different, the product inside the vial is the same MK-3475 drug product.
Pembrolizumab (MK-3475) Solution for Infusion vials are filled to a target of 4.25mL 
(106.25mg) to ensure recovery of 4.0mL (100mg).
16.2 3.2 STABILITY AND HANDLING OF DRUG PRODUCT
Pembrolizumab (MK-3475) Solution for Infusion, 100 mg/ 4 mL vial :  pembrolizumab 
(MK-3475) Solution for Infusion vials should be stored at refrigerated conditions 2 – 8 °C (36 
- 46 °F) and protected from light.
To determine whether to report a temperature excursion, the temperature values should be 
rounded to whole numbers.
Rounding:
oDecimal values from 0.1 to 0.4 round down to the nearest whole number 
(e.g., 8.3 = 8)
oDecimal values from 0.5 to 0.9 round up to the nearest whole number 
(e.g., 8.7 = 9)
Then compare the rounded values to the required temperature range to determine if there's 
an excursion.
All temperature excursions, however small, must be reported by the site to the Clinical 
Complaint Intake mailbox (clinical.complaints.intake@merck.com) for investigation within 
1 business day using the Clinical Supply Complaint & GCP Inquiry Form (excel version) 
and attached temperature data.  All Clinical Supply stock that is subject to an investigation 
must be placed in quarantine and remain unavailable to dispense to patients until disposition 
has been determined.
Please note temperature excursions after drug product is prepared are out of scope of the 
clinical complaint process. Please contact HQ clinical study team for further guidance. 
Note: vials should be stored in the original box to ensure the drug product is protected    from 
light.
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
81Pembrolizumab (MK-3475) infusion solutions should be prepared in 0.9% Sodium Chloride 
Injection, USP (normal saline) or regional equivalent or 5% Dextrose Injection, USP (5% 
dextrose) or regional equivalent and the final concentration of pembrolizumab (MK-3475)  in 
the infusion solutions should be between 1 mg/mL and 10 mg/mL. 
Please note, the preferred diluent is 0.9% Sodium Chloride and 5% dextrose is only 
permissible if normal saline is not available.
Local guidelines should be followed for collection of diluent information such as 
manufacturer, lot and expiry. When the diluent is provided by Merck, the drug accountability 
log should be used for collection of diluent information.
Pembrolizumab (MK-3475) SHOULD NOT BE MIXED WITH OTHER DILUENTS. 
Pembrolizumab (MK-3475) solutions may be stored at room temperature for a cumulative 
time of up to 6 hours. The 6 hour countdown begins when the vial is pierced, and includes 
room temperature storage of admixture solutions in the IV bags and the duration of infusion. 
(Please note this 6 hour timeframe is to provide a microbial control strategy. The microbial 
clock only starts when the product stopper is pierced and not when the vial is removed from 
the refrigerator.)
In addition, IV bags may be stored under refrigeration at 2 °C to 8 °C (36 °F to 46 °F), total 
cumulative storage time at room temperature and refrigeration should not exceed 24 hours. 
If refrigerated, allow the IV bags to come to room temperature prior to use.  
Parenteral drug products should be inspected visually for particulate matter and discoloration 
prior to administration. Discard the drug product vial if visible particles are observed.
   Sites should follow their SOPs for drug transport and delivery, with all possible effort to 
minimize agitation of the drug product between the pharmacy and the clinic
DO NOT USE PEMBROLIZUMAB (MK-3475) IF DISCOLORATION IS 
OBSERVED.
DO NOT SHAKE OR FREEZE THE VIAL(S).
DO NOT ADMINISTER THE PRODUCT AS AN INTRAVENOUS (IV) PUSH OR 
BOLUS.
DO NOT COMBINE, DILUTE OR ADMINISTER IT AS AN INFUSION WITH 
OTHER MEDICINAL PRODUCTS.
Any departure from the guidance listed in this manual, must be discussed with sponsor
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
8216.3 3.3 DOSE CALCULATION
Follow directions applicable to the dose level (mg/kg) of the study.
200 mg Fixed Dose
 2 vials (100 mg/4 mL)
 8 mL total 
16.4 4.4 PREPARATION OF INFUSION SOLUTION
Aseptic technique must be strictly observed throughout the preparation procedure 
   Use of a biosafety cabinet is preferred since no anti-microbial preservative is present in the 
product; however, it is not mandatory unless specified by site standard operating procedure.
Equilibrate required number of pembrolizumab MK-3475 vials to room temperature
The preferred method of dose preparation is the volumetric method
Sponsor recommends reconstitution and administration of pembrolizumab (MK-3475) that 
follows the parameters in this manual, however if use of gravimetric preparation is mandatory 
due to local site procedures, the following requirements must be satisfied and documented:
Draw the required volume up to 4.0 mL (100 mg) of pembrolizumab from each vial
Limit the number of punctures of each vial to one
For gravimetric preparation method using density of pembrolizumab solution, a value of 1.03 
g/mL should be used
Merck does not support methods of preparation of non-Merck agents beyond what is stated 
in the product literature.  Sites should reference the SmPCs or packaging inserts for 
preparation instructions
If the site procedures require use of spikes or other closed system transfer devices (CSTDs), 
please contact sponsor for approval
Choose a suitable infusion bag size so that the following conditions are met:
Concentration of pembrolizumab MK-3475 is between 1 mg/mL and 10 mg/mL
The infusion volume to bag capacity ratio should not be less than 0.3.  In other 
words, the bag must be filled to at least 30% of its capacity.  
Choose a suitable infusion bag material. The bag may be empty or it may contain normal 
saline The following infusion bag materials are compatible with pembrolizumab (MK-3475): 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
83PVC plasticized with DEHP
Non-PVC (polyolefin)
EVA
PE lined polyolefin
      *Contact Sponsor for materials not listed above
Calculate the volume of pembrolizumab (MK-3475) and normal saline required to prepare 
the infusion (admixture) bag
Volume of pembrolizumab (MK-3475) (mL) = required dose amount (mg) / 25 (mg/mL)
Volume of normal saline = total infusion volume – volume of pembrolizumab (MK-3475) 
from above
If a bag pre-filled with normal saline is being used, remove the excess volume of normal saline 
using a sterile syringe (Polypropylene, latex-free) attached to a suitable needle. Keep in 
consideration the excess bag fill volume as well as the volume of pembrolizumab (MK-3475) 
to be added to the bag to prepare the infusion solution. This helps ensure that the concentration 
in the bag can be accurately calculated and falls within the acceptable range of 1 mg/mL to 
10 mg/mL. If the site would like to proceed without removing excess saline they must ensure 
that the concentration of MK-3475 would still fall within acceptable range.
If an empty bag is being used, withdraw the necessary volume of normal saline from another 
appropriate bag and inject into the empty bag. Keep in consideration the volume of 
pembrolizumab (MK-3475) to be added to the bag to prepare the infusion solution.
Withdraw the required volume of pembrolizumab (MK-3475)  from the vial(s) (up to 4 mL 
from each vial) using a sterile syringe attached to a suitable needle. The vial(s) may need to 
be inverted to remove solution.
Volume of pembrolizumab (MK-3475) (mL) = required dose amount (mg) / 25 (mg/mL)
Note: If it is necessary to use several vials, it is advisable to withdraw from several vials into 
a suitable size single use syringe using a new needle for each vial. 
Add the required pembrolizumab (MK-3475) into the infusion IV bag containing normal 
saline and gently invert the bag 10-15 times to mix the solution.
Pembrolizumab (MK-3475) solutions may be stored at room temperature for a cumulative 
time of up to 6 hours. This includes room temperature storage of admixture solutions in the 
IV bags and the duration of infusion. 
In addition, IV bags may be stored under refrigeration at 2 °C to 8 °C (36 °F to 46 °F), total 
cumulative storage time at room temperature and refrigeration should not exceed 24 hours. 
If refrigerated, allow the IV bags to come to room temperature prior to use.  
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
84If the infusion bag is excessively handled or shaken, particulates may form. If this occurs 
discard the bag and create a new bag taking care not to shake. Please contact your HQ clinical 
study team if particulates are noticed for further instructions.  Be prepared to provide the 
following information:
IV bag manufacture, lot and expiry
Target volume of admixture solution in the IV bag (e.g. 100 mL, 200 mL etc.)
Amount of drug product (mL or mg) added to the bag
Drug product lot
Brief description of the nature of visible particles (color, shape, size, numbers etc.).
 
DO NOT FREEZE THE PEMBROLIZUMAB (MK-3475) INFUSION SOLUTION.
Discard any unused portion left in the vial as the product contains no preservative
16.5 3.5 ADMINISTRATION
Pembrolizumab (MK-3475) infusions should be administered in 30 minutes, with a window 
of -5 and +10 minutes, using an infusion pump. A central catheter is not required for infusion; 
however, if a subject has a central venous catheter in place, it is recommended that it be used 
for the infusion. 
The following infusion set materials are compatible with (pembrolizumab) MK-3475:
oPVC Infusion set that is plasticized using DEHP
oPVC and tri-(2-ethylhexyl) trimellitate (TOTM) infusion set
oPolyethylene lined PVC infusion set
oPVC Infusion set that is plasticized using Di-2-ethylhexyl Terephthalate (DEHT)
oPolyurethane set
*Contact Sponsor for materials not listed above
A sterile, non-pyrogenic, low-protein binding 0.2 to 5 µm in-linefilter made of 
polyethersulfone (PES) must be used during administration to remove any adventitious 
particles.  If the infusion set does not contain 0.2 to 5 µm in-line filter, it is recommended to 
use 0.2 to 5 µm add-on filter which may contain an extension line (Note: the materials of the 
extension line and filter should be as mentioned above).
Attach the infusion line to the pump and prime the line, either with normal saline (at least 25 
mL) or with infusion solution as per local SOP, before starting the infusion.
Infuse pembrolizumab (MK-3475) over approximately 30 minutes, with a window of 
        -5 and +10 minutes, through a peripheral line or indwelling catheter. 
Ensure the entire contents of the bag are dosed and all remaining drug solution in the line is 
administered through saline flushing. 
DF/HCC Protocol #: 16-301
Protocol Version Date: 29-JUL-2021
85Document volume administered according to data entry guidelines.
In case of infusion reactions, infusion rate may differ; refer to protocol for specific 
instructions. 
Whenever possible, the lowest infusion rate should be used that will allow completion of the 
infusion within the 30 minutes. 
Maximum rate of infusion should not exceed 6.7 mL/min. through a peripheral line or 
indwelling catheter. 
However, when it is necessary to infuse a larger volume (i.e. 250 mL), the flow rate may go 
as high as 10 mL/min (maximum) in order to keep the infusion within the window as defined 
above. 
DO NOT CO-ADMINISTER OTHER DRUGS THROUGH THE SAME INFUSION 
LINE.
UNUSED INFUSION SOLUTION FOR INJECTION SHOULD NOT BE USED FOR 
ANOTHER INFUSION OF THE SAME SUBJECT OR DIFFERENT SUBJECT.
Caution: Do not shake the vials/bags otherwise this may result in formation of foam. If 
foam is noticed in either vial or bag, the drug product will need to be discarded. A new 
preparation should be made, taking care not to shake or agitate the product.
16.6 3.6 RETURN AND DISCARDING OF PEMBROLIZUMAB (MK-3475) VIALS
Unused pembrolizumab (MK-3475) Solution for Infusion vial(s) shall be returned to the 
designated facility for destruction.
oFor US clinical sites, return to the central depot that shipped supplies to the site: 
Fisher Clinical Services, Return and Destruction Center, 700B Nestle Way, 
Breinigsville, PA 18031
Merck & Co., Inc. 770 Sumneytown Pike B-78A West Point, PA 19486
oFor ex-US clinical sites, consult with local Merck subsidiary for facility address.
    Solution remaining in a used vial should be discarded according to your local procedures.
    Any information on the label identifying the subject should be redacted prior to returning 
the study medication.
1  
    
 
DFCI IRB Prot ocol #: 16-301  
     
APPENDIX F  
 
Dana-Farber/Harvard Cancer Center 
Multi-Center Data and Safety Monitoring Plan 
          
 
 
                  
 
2  
TABLE OF CONTENTS 
1.  INTRODUCTION ...............................................................................................................3  
1.1 Purpose .....................................................................................................................3  
1.2 Multi-Center Data and Safety Monitoring Plan Definitions ....................................3  
2.  GENERAL ROLES AND RE SPONSIBILITIES ...............................................................4  
2.1 DF/HCC Sponsor .....................................................................................................4  
2.2 Coordinating Center .................................................................................................5  
2.3 Participating Institution ............................................................................................5  
3.  DF/HCC REQUIREMENTS FOR MU LTI-CENTER PROTOCOLS................................6  
3.1 Protocol Distribution ................................................................................................6  
3.2 Protocol Revisions and Closures .............................................................................6  
3.3 Informed Consent Requirements .............................................................................7  
3.4 IRB Documentation .................................................................................................7  
3.5 IRB Re-Approval .....................................................................................................7  
3.6 Participant Confidentiality a nd Authorization Statement ........................................8  
3.7 DF/HCC Multi-Center Protoc ol Registration Policy ...............................................8  
3.8 DF/HCC Protocol Case Number ..............................................................................9  
3.9 Protocol Deviations, Excep tions and Violations .....................................................9  
3.10 Safety Assessments and Toxicity Monitoring .......................................................10  
3.11 Data Management ..................................................................................................11  
4.  REQUISITIONING INVESTIGATIONAL DRUG..........................................................11  
5.  MONITORING: QUALITY CONTROL ..........................................................................11  
5.1 Ongoing Monitoring of Protocol Compliance .......................................................12  
5.2 Monitoring Reports ................................................................................................12  
6.  AUDITING: QUALITY ASSURANCE ...........................................................................13  
6.1 Audit Plan: DF/HCC Sponsored Trials..................................................................13  
6.2 Audit Notification ..................................................................................................13  
6.3 Audit Reports .........................................................................................................13  
6.4 Participating Institution Performance ....................................................................13  
 
 
3  
1. INTRODUCTION 
 
The Dana-Farber/Harvard Cancer Center Multi-Center Data and Safety Monitoring Plan 
(DF/HCC DSMP) outlines the procedures for conducting a DF/HCC Mu lti-Center research 
protocol. The DF/HCC DSMP shou ld serve as a reference for any sites external to DF/HCC 
that will be participating in the research protocol. 
 
1.1 Purpose 
 
To establish standards that will ensure that  a Dana-Farber/Harvard Cancer Center Multi-
Center protocol will comply with Federal Regulations, Health Insu rance Portability and 
Accountability Act (HIPAA) requirements and applicable DF/HCC Standard Operating 
Procedures .        
 
1.2 Multi-Center Data and Safety Monitoring Plan Definitions 
 
DF/HCC Multi-Center Protocol :  A research protocol in which one  or more outside 
institutions are collaborating with Dana-Farbe r/Harvard Cancer Center where  a DF/HCC 
investigator is the sponsor. DF/HCC includes Dana-Farber/Partners Cancer Care (DF/PCC) Network Clinical Trial Affiliates.  
 Lead Institution:  One of the  Dana-Farber/Harvard Cancer Center consortium members 
(Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH), Beth Israel Deaconess Medical Center (BIDMC), Boston Children’s Hospital (BCH), Brigham 
and Women’s Hospital (BWH)) responsible for the coordination, development, 
submission, and approval of a protocol as well as its subsequent amendments per the 
DFCI IRB and applicable regulatory guide lines (CTEP, Food and Drug Administration 
(FDA), Office of Biotechnology Activities (OBA) et c.).  The Lead Institution is typically 
the home of the DF/HCC Sponsor. The Lead In stitution also typica lly serves as the 
Coordinating Center for the DF /HCC Multi-Center Protocol.   
 DF/HCC Sponsor:  The person sponsoring the submitted Multi-Center protocol.  Within 
DF/HCC, this person is the Overall Principa l Investigator who ta kes responsibility for 
initiation, management and conduct of the protocol  at all research loca tions. In applicable 
protocols, the DF/HCC Sponsor will serve as the single liaison with any regulatory agencies. The DF/HCC Sponsor has ultimate authority over the protocol and is responsible for the conduct of the study at DF/HCC and all Pa rticipating Institutions. In most cases the 
DF/HCC Sponsor is the same person as the DF/HCC Overall Prin cipal Investigator; 
however, both roles can be filled by two different people. 
 
Participating Institution:  An institution that is outside the DF/HCC and DF/PCC 
consortium that is collabor ating with DF/HCC on a protoc ol where the sponsor is a 
DF/HCC Investigator.  The Participating Institution ac knowledges the DF/HCC Sponsor 
as having the ultimate authorit y and responsibility for the overa ll conduct of the study.    
 
 
4 Coordinating Center: The entity (i.e. Lead Institution, Medical Monitor, Contract 
Research Organization (CRO), etc) that provides administra tive support to the DF/HCC 
Sponsor in order that he/she may fulfill th e responsibilities outlined in the protocol 
document and DSMP, and as specified in app licable regulatory guidelines (i.e. CTEP 
Multi-Center Guidelines). In general, the L ead Institution is the Coordinating Center for 
the DF/HCC Multi-Center Protocol. Should th e DF/HCC Sponsor deci de to use a CRO, 
the CRO will be deemed the Coordinating Center.   
 DF/HCC Office of Data Quality: A group within DF/HCC responsible for registering 
human subjects for trials, ensuring high-quality standards are used for data collection and 
the ongoing management of clinical trials, a uditing, and data and sa fety monitoring. ODQ 
also coordinates quality assurance efforts related to multi-center clinical research.  
 2. GENERAL ROLES AND RESPONSIBILITIES 
For DF/HCC Multi-Center Protocols, the DF/HCC Sponsor, the Coordinating Center, and the Participating Institutions are expected to adhere to the following general responsibilities:  
 
2.1 DF/HCC Sponsor 
 The DF/HCC Sponsor, James Cleary, MD, PhD,  will accept responsibility for all aspects 
of conducting a DF/HCC Multi-Center protocol  which includes but is not limited to:  
 Oversee the coordination, development, submission, and approval of the protocol 
as well as subsequent amendments.  
 Ensure that the investigators, study team  members, and Participating Institutions 
are qualified and appropriately resour ced to conduct the protocol.   
 Include the Multi-Center Data and Safety Monitoring Plan as an appendix to the 
protocol. 
 Ensure all Participating Institutions are using the correct vers ion of the protocol. 
 Ensure that each participating investig ator and study team member receives 
adequate protocol training and/or a Si te Initiation Visit prior to enrolling 
participants and throughout trial’s conduct as needed. 
 Ensure the protocol will be provided to each particip ating site in a language 
understandable to all appli cable site personnel when English is not the primary 
language.  
 Monitor progress and overall conduct of the study at all Participating Institutions.  
 Ensure all DFCI Institutional Review Bo ard (IRB), DF/HCC and other applicable 
reporting requirements are met.  
 Review data and maintain timely subm ission of data for study analysis.  
 Act as the single liaison with the FDA (inve stigator-held IND trials), as applicable. 
 Ensure compliance with all requirements as set forth in the Code of Federal 
Regulations, applicable DF/HCC require ments, HIPAA requirements, and the 
approved protocol. 
 Commit to the provision that the protocol  will 
 not be rewritten or modified by 
anyone other than the DF/HCC Sponsor. 
 
5  Identify and qualify Participating Institutions and obtain accrual commitments 
prior to extending the pr otocol to that site. 
 Monitor accrual and address Participating Institutions that are not meeting their 
accrual requirements.  
 
2.2 Coordinating Center  
 
The general responsibilit ies of the Coordinating Center ma y include but are not limited to: 
 Assist in protocol development.  
 Maintain FDA correspondence, as applicable. 
 Review registration materials for eligibility and register participants from Participating Institutions with DF/HCC ODQ. 
 Distribute protocol and informed consent document updates to Participating 
Institutions as needed. 
 Oversee the data collection proce ss from Participating Institutions. 
 Maintain documentation of Serious  Adverse Event (SAE) reports and 
deviations/violation submitted by Participating Institutions and provide to the DF/HCC Sponsor for timely review.   
 Distribute serious adverse events reported to the DF/H CC Sponsor that fall under 
the DFCI IRB Adverse Event Reporting Po licy to all Participating Institutions. 
 Provide Participating Institutions w ith information regarding DF/HCC 
requirements that they will be expected to comply with.  
 Carry out plan to monitor Participating In stitutions either by on-site or remote 
monitoring.  
 Maintain Regulatory documents of all Part icipating Institutions which includes but 
is not limited to the following: local IRB approvals/notifications from all Participating Institutions, confirmation of Federalwide Assurances (FWAs) for all 
sites,  all SAE submissions, Screening L ogs for all sites, I RB approved consents 
for all sites 
 Conduct regular communications  with all Participating Institutions (conference 
calls, emails, etc) and maintain docum entation all releva nt communications. 
 
2.3 Participating Institution 
 Each Participating Institution is expected to comply with all applicable federal regulations 
and DF/HCC requirements, the prot ocol and HIPAA requirements.  
 
The general responsibilities for each Particip ating Institution may include but are not 
limited to: 
 Document the delegation of research specific activities to study personnel. 
 Commit to the accrual of participants to the protocol. 
 Submit protocol and/or amendm ents to their local IRB. 
 Maintain regulatory files as per sponsor requirements. 
 Provide 
the Coordinating Ce nter with regulatory documents or source documents 
as requested. 
 
6  Participate in protocol trai ning prior to enroll ing participants and throughout the 
trial as required (i.e . teleconferences). 
 Update Coordinating Center with res earch staff changes on a timely basis. 
 Register participants through the Coordina ting Center prior to beginning research 
related activities.  
 Submit Serious Adverse Event (SAE) report s to local IRB per local requirements 
and to the Coordinating Center, in accordance with DF/HCC requirements. 
 Submit protocol deviations and violations to local IRB per local requirements and 
to the DF/HCC Sponsor in accordance with DF/HCC requirements. 
 Order, store and dispense investigationa l agents and/or other protocol mandated 
drugs per federal guidelines and protocol requirements. 
 Have office space, office equipment, and internet access that meet HIPAA 
standards. 
 Participate in any quality assurance activitie s and meet with monitors or auditors at 
the conclusion of a visit to review findings. 
 Promptly provide follow-up and/or corre ctive action plans for any monitoring 
queries or audit findings. 
 
3. DF/HCC REQUIREMENTS FOR MULTI-CENTER PROTOCOLS 
The following section will clarify DF/HCC Require ments and further detail the expectations 
for participating in a DF/HCC Multi-Center protocol.  
 
3.1 Protocol Distribution 
 
The Coordinating Center will distribute the final DFCI IR B approved protocol and any 
subsequent amended protocols to all Participating Institutions.    
 
3.2 Protocol Revisions and Closures 
 The Participating Institutions will receive not ification of protocol revisions and closures 
from the Coordinating Center.  It is the individual Participa ting Institution’s responsibility 
to notify its IRB of these revisions. 
 
 Non life-threatening revisions:  Participating Institutions will receive written 
notification of protocol re visions regarding non life-th reatening events from the 
Coordinating Center. Non-life-threaten ing protocol revisions must be IRB 
approved and implemented within 90 days from receipt of the notification. 
 
 Revisions for life-threatening causes: Participating Institu tions will receive 
immediate notification from the Coordinating Center concerning protocol revisions 
required to protect lives w ith follow-up by fax, mail, e-mail, etc.  Life-threatening 
protocol revisions will be implemente d immediately followed by IRB request for 
approval. 
 
 Protocol closures and temporary holds:  Participating In 
stitutions will receive 
notification of protocol closures and temporary hol ds from the Coordinating 
 
7 Center. Closures and holds  will be effective immediately.  In addition, the 
Coordinating Center, will update the Par ticipating Institutions on an ongoing basis 
about protocol accrual data so that they will be aw are of imminent protocol 
closures. 
 
3.3 Informed Consent Requirements 
 
The DF/HCC approved informed consent doc ument will serve as a template for the 
informed consent for Participating Institutions. The Participating Institution consent form must follow the consent template as closely as possible and should adhe re to specifications 
outlined in the DF/HCC Guidance Document on Model Consent Language for PI-Initiated 
Multi-Center Protocols.  This document will be  provided separately to each Participating 
Institution.  Participating Institutions are to send their version of the informed consent document and HIPAA authorization, if a separate document , to the Coordinating Center for review and 
approval prior to submission to their local IRB. The approved consent form must also be submitted to the Coordinating Center after approval by the local IRB for all consent 
versions.  The Principal Investigator (PI) at each Participating Instit ution will iden tify the physician 
members of the study team who will be obtaining consent and signing the consent form for therapeutic protocols. Participating inst itutions must follow the DF/HCC requirement 
that only attending physicians obtain informed consent and re-consent to interventional trials (i.e. drug and/or  device trials).   
 
3.4 IRB Documentation 
 The following must be on file with the Coordinating Center: 
 Initial approval letter of the Participating Institution's IRB.  
 Copy of the Informed Consent Form(s) approved by the Participating Institution’s 
IRB.  
 Participating Institution’s I RB approval for all amendments. 
 Annual approval letters by the Par ticipating Institution's IRB. 
 
  
3.5 IRB Re-Approval 
 Verification of IRB re-approval from the Particip ating Institutions is required in order to 
continue research activities.  There is no grace period for continuing approvals.  
 
The Coordinating Center will not register partic ipants if a re-approval letter is not received 
from the Participating Institution on or before the anniversary of the previous approval date.   
 
 
8  
3.6 Participant Confidentiality and Authorization Statement 
 
In 1996, congress passed the first federal law covering the privacy of  health information 
known as the Health Insurance Portability  and Accountability Act (HIPPA). Any 
information, related to the physical or mental health of an individual is called Protected 
Health Information (PHI). HIPAA outlines how and under what circumstances PHI can be 
used or disclosed.   In order for covered entities to use or disclo se protected health in formation during the 
course of a study, the study participant must sign an authorization statement.  This 
authorization statement may or may not be separate from the informed consent document.  
The Coordinating Center, with the approval from the DFCI IRB will provide a consent 
template, with information regarding authorizat ion for the disclosure of protected health 
information.   The DF/HCC Sponsor will use all efforts to limit its use of protected health information in 
its trials. However, because of the nature of these trials, certain protected health 
information must be collected. DF/HCC has c hosen to use authorizations, signed by the 
participant in the trial, rather than lim ited data sets with data use agreements. 
 
3.6.1  DF/HCC Multi-Center Prot ocol Confidentiality 
 
All documents, investigative reports, or inform ation relating to the participant are strictly 
confidential. Whenever reasona bly feasible, any participant specific reports (i.e. Pathology 
Reports, MRI Reports, Operative Reports, et c.) submitted to the Coordinating Center 
should be de-identified. It is recommended that the assigned DF/HCC ODQ case number 
(as described below) be used for all partic ipant specific documents. Participant initials 
may be included or retained for cr oss verification of  identification.  
 
3.7 DF/HCC Multi-Center Protocol Registration Policy 
 
Refer to protocol section 6.4 for registration procedures.  
 
3.7.1  Initiation of Therapy 
 
Participants must be registered with the DF/HCC ODQ before
 receiving treatment.  
Treatment may not be initiated until the Participating Institu tion receives confirmation of 
the participant’s registration from the C oordinating Center. The DF/HCC Sponsor and 
DFCI IRB must be notified of a ny violations to this policy. 
 
3.7.2  Eligibility Exceptions 
 The DF/HCC ODQ will make no exceptions to th e eligibility requirements for a protocol 
without DFCI IRB approval. The DF/HCC ODQ re quires each institution to fully comply 
with this requirement. 
 
 
9 3.8 DF/HCC Protocol Case Number 
 
At the time of registration, ODQ requires the follo wing identifiers for al l subjects: initials, 
date of birth, gender, race and ethnicity. Once  eligibility has been established and the 
participant successfully registered, the part icipant is assigned a unique protocol case 
number.  Participating Institutions shoul d submit all de-identified subsequent 
communication and documents to the Coordinating Center, using this case number to 
identify the subject.    
3.9 Protocol Deviations, Exceptions and Violations 
 Federal Regulations require an IRB to review proposed change s in a research activity to 
ensure that researchers do not initiate cha nges in approved research without IRB review 
and approval, except when necessary to el iminate apparent immediate hazards to the 
participant. DF/HCC requires all departures from the defined procedures set forth in the IRB approved protocol to be reported to the DF/HCC Sponsor, who in turn is responsible 
for reporting to the DFCI IRB.   For reporting purposes, DF/HCC uses the terms “violation”, “deviation” and “exception” 
to describe departures from a protocol. All Participating Inst itutions must adhere to these 
requirements for reporting to the DF/HCC Sp onsor and will follow their institutional 
policy for reporting to their local IRB. 
 
3.9.1  Definitions 
 
Protocol Deviation
: Any departure from the defined procedures set forth in the IRB-
approved protocol which is prospectively approved  prior to its implementation. 
 Protocol Exception
:  Any protocol deviation that relate s to the eligibility criteria, e.g. 
enrollment of a participant who does not meet all inclusion/exclusion criteria. 
   Protocol Violation
: Any protocol deviation that was not prospectively approved  by the 
IRB prior to its initiati on or implementation.   
 
3.9.2  Reporting Procedures 
 
DF/HCC Sponsor:  is responsible for ensu ring that clear documenta tion is available in the 
medical record and/or regulatory documents to describe all protocol exceptions, deviations 
and violations. The DF/HCC Sponsor will al so be responsible fo r ensuring that all 
protocol violations/deviati ons are promptly reported per DFCI IRB guidelines.  
 Participating Institutions
: Protocol deviations require pr ospective approval from the DFCI 
IRB. The Participating Institution must subm it the deviation request to the Coordinating 
Center who will then submit the deviation request to the DFCI IRB. Upon DFCI IRB 
approval the deviation is submitted to the Par ticipating Institution IRB, per institutional 
policy. A copy of the Participating Institut ion’s IRB report and determination will be 
 
10 forwarded to the Coordinating Center with in 10 business days after the original 
submission.  
 All protocol violations must be sent to the Coordinating Center in a timely manner.  
 Coordinating Center:
  Upon receipt of the violation/devi ation report from the Participating 
Institution, the Coordinating Center will s ubmit the report to the DF/HCC Sponsor for 
review. Subsequently, the Participating Institu tion’s IRB violation/deviation report will be 
submitted to the DFCI IRB for review per DFCI IRB reporting guidelines. 
 
3.10 Safety Assessments and Toxicity Monitoring 
 The study teams at all particip ating institutions ar e responsible for protecting the safety, 
rights and well-being of study participants. Recording and repor ting of adverse events that 
occur during the course of a study help ensure the continuing safety of study participants.   All participants receiving investigational agents will be evaluated for safety. The safety parameters include all laboratory tests and hematological abnormalities, physical 
examination findings, and spontaneous reports of  adverse events reported by participants.  
All toxicities encountered during the study will be evaluated according to the NCI criteria 
specified in the protocol. Life -threatening toxicities must be  reported immediately to the 
DF/HCC Sponsor via the Coordinating Center. 
 
Additional safety assessments and toxicity monitoring will be outlined in the protocol. 
 
3.10.1 Guidelines for Reporting Serious Adverse Events  
 
Guidelines for reporting Adverse Events (A Es) and Serious Adverse Events (SAEs) are 
detailed in protocol section 9 .      
 
Participating Institutions must report the SAEs to the DF/HCC Sponsor and the 
Coordinating Center following the  DFCI IRB Adverse Event Reporting Policy
. 
 
The Coordinating Center will maintain documentation of all Participating Institution Adverse Event reports and be responsible  for communicating to all participating 
investigators, any observations reportable under the DFCI IRB Repor ting Requirements.  
Participating Institutions will review and submit to their IRB according to their institutional policies and procedures 
 
3.10.2 Guidelines for Processing IND Safety Reports  
 
The DF/HCC Sponsor will review  all IND Safety Reports and ensure that all IND Safety 
Reports are distributed to the Participating Institutions. Participating Institutions will review and submit to their IRB according to their institutional policies and procedures. 
  
 
11 3.11 Data Management 
 
The DF/HCC ODQ develops case report forms (CRF/eCRFs), for use with the protocol.  
These forms are designed to collect data  for each study. The DF/HCC ODQ provides a 
web based training for eCRF users. 
   
3.11.1 Data Forms Review 
 
Data submissions are monitored for time liness and completeness of submission. 
Participating Institutions are notified of their data submission delinquencies in accordance 
with the following:  Incomplete or Questionable Data
 
If study forms are received with missing or questionable data, the submitting institution 
will receive a written or electronic que ry from the DF/HCC ODQ Data Analyst, 
Coordinating Center or designee.  Responses to  all queries should  be completed and 
submitted within 14 calendar days.  Responses ma y be returned on the written query or on 
an amended paper case report form, or in th e case of electronic queries, within the 
electronic data capture (eDC) system. In the ca se of a written query for data submitted on 
a paper case report form, the query must be attached to the specific data being re-
submitted in response.    Missing Forms
 
If study forms are not submitted on schedule, th e Participating Institution will receive a 
Missing Form Report from the Coordinating Center noting the missing forms.  These reports are compiled by the DF/HCC ODQ a nd distributed on a monthly basis.  
 
4. REQUISITIONING INVESTIGATIONAL DRUG 
 
Participating Institutions will order their own investigational agent (Pembrolizumab) directly 
from Merck using the Drug Supply Request Form. Please allow for 3 weeks for drug to arrive after the order is submitted. The Participating Institution will ensure that the pharmacy will be able to receive and store the agent accord ing to state and federal guidelines. The local 
IRB should be kept informed of who will s upply the agent (i.e., Merck pharmaceuticals Inc.) 
so that any regulatory responsibilitie s can be met in a timely fashion. 
 
 
5. MONITORING: QUALITY CONTROL 
 
The quality control process for a clinical tria l requires verification of protocol compliance 
and data accuracy. The Coordi nating Center, with the aid of the ODQ provides quality 
control oversight for the protocol. 
   
 
12 5.1 Ongoing Monitoring of Protocol Compliance 
 
The Participating Institutions will be requir ed to submit participant source documents to 
the Coordinating Center for monitoring. Participa ting Institution will also be subject to at 
least one on-site monitoring conducted by th e Coordinating Center’s Clinical Trial 
Specialist. 
 The Coordinating Center will implement ongoi ng monitoring activities  to ensure that 
Participating Institutions are complying with  regulatory and protocol  requirements, data 
quality, and participant safet y. Monitoring will occur before  the clinical phase of the 
protocol begins, continue during protocol performance and through study completion. 
Additional monitoring practices  may include but are not lim ited to; source verification, 
review and analysis of the following: eligibility  requirements of all participants , informed 
consent procedures, adverse events and all associated doc umentation, study drug 
administration/treatment, regulatory files, prot ocol deviations, pharmacy records, response 
assessments, and data management.  The DF/HCC Lead Institution will mainta in regular and ongoing communication to 
Participating Institutions a bout study related information. 
 On-Site Monitoring will occur at least once per non DF/HCC site. Initial site visit to occur 
after first participant is enrolled or after study has been activated for 9 months, whichever 
comes first. Additional on-site monitoring may occur at the request of the DF/HCC 
Sponsor. Participating Institutions will be required to provide access to participants’ complete medical record and source documen ts for source documentation verification and 
Site Regulatory Binder. 
 
Virtual Monitoring will take place for verifi cation of informed consent and eligibility, 
study visit source documents and CRF, investig ational product accounta bility, CRF review 
for missing data and query resolution, AEs, SA Es, and protocol endp oints unless on-site 
monitoring is requested by the DF/HCC Sponsor. Participating Institutions will be required 
to forward de-identified copies of participants’ medical record  and source documents to the 
Coordinating Center. 
 
All data submitted to the DF/HCC ODQ will be  monitored for timeliness of submission, 
completeness, and adherence to protocol requirements. The Coordi nating Center and if 
applicable, ODQ Data Analysts assigned to th e protocol, will perf orm the ongoing protocol 
data compliance monitoring. 
 
5.2 Monitoring Reports 
 
The DF/HCC Sponsor will review all monitoring reports for on-site and remote 
monitoring of Participating Institutions to ensure protocol compliance. The DF/HCC 
Sponsor may increase the monitoring activities at  Participating Institu tions that are unable 
to comply with the protocol, DF/HCC S ponsor requirements or federal and local 
 
13 regulations. Participating Institutions may also be subject to an audit as determined by the 
DF/HCC Sponsor. 
 
 
6. AUDITING: QUALITY ASSURANCE 
 
Auditing is a method of Quality Assurance. Its main focus is to measure whether standards 
and procedures were followed. Auditing is the systematic and independent examination of 
all trial related activities and documents.  Au dits determine if evaluated activities were 
appropriately conducted and whether data wa s generated, recorded and analyzed, and 
accurately reported per the protocol, Standard Operating Procedures (SOPs), and the Code 
of Federal Regulations (CFR). 
 
6.1 Audit Plan: DF/HCC Sponsored Trials 
 Auditing of this protocol w ill take place as determined by DFCI ODQ. One on-site audit 
will be scheduled by the ODQ, a ssuming at least three particip ants have been  treated on 
protocol at the site. Approximately 3-4 particip ants would be audited at the site over a 2 
day period.  If violations which impact particip ant safety or the inte grity of the study are 
found, more participant r ecords may be audited.  
 
6.2 Audit Notification 
 
It is the Participating Institution’s responsibility to notify the Coordinating Center of all scheduled audit dates (interna l or NCI) and re-audit dates (if applicable), which involve 
this protocol. All institutions will forward a c opy of final audit and/ or re-audit reports and 
corrective action plans (if applicable) to th e Coordinating Center, within 12 weeks after 
the audit date.  
 
6.3 Audit Reports  
 
The DF/HCC Sponsor will review  all final audit reports and corrective action plans if 
applicable. The Coordinating Ce nter, must forward these re ports to the DF/HCC ODQ per 
DF/HCC policy for review by the DF/HCC  Audit Committee. Based upon the audit 
assessments the DF/HCC Audit Committee c ould accept or conditionally accept the audit 
rating and final report. Conditional approva l could require the DF/HCC Sponsor to 
implement recommendations or require furt her follow-up.  For unacceptable audits, the 
DF/HCC Audit Committee would forward the fina l audit report and co rrective action plan 
to the DFCI IRB as applicable. 
 
6.4 Participating Institution Performance 
 
The DF/HCC Sponsor, DFCI IRB is charged with considering th e totality of an 
institution’s performance in considering institutional participation in the protocol. 
 
 
14 6.4.1 Corrective Actions 
 
Participating Institutions that fail to meet the performance goals of accrual, submission of 
timely and accurate data, adherence to protoc ol requirements, and compliance with state 
and federal regulations, may be recommended for a six-month probation period. Such 
institutions must respond with a corrective action plan and must demonstrate during the 
probation period that deficien cies have been corrected, as evidenced by the improved 
performance measures. Particip ating Institutions that fail to demonstrate significant 
improvement will be considered by the DF/HCC Sponsor for revocation of participation. 
A DF/HCC Sponsor and/or the DFCI IRB may terminate a site’s participation if it is 
determined that a site is not fulfilling its responsibilities as described above. 
 
   
   
Protocol #16-301: Drafted (8/10/16)(CG)/Approved (8/11/16)(LC) 
 DANA-FARBER CANCER INSTITUTE 
Nursing Protocol Education Sheet 
Protocol Number: 16-301 
Protocol Name: A Multicenter Phase 2 Clinical Trial of Pembro lizumab in Refractory Metastatic Anal Cancer  
DFCI Site PI: James Cleary, MD 
DFCI Research Nurse: Christopher  Graham, RN, BSN ; Laura Casadonte,  RN 
Page the DFCI research nurse or DFCI site PI if there are any questions/concerns about the protocol.   
Please also refer to ONC 15 : Oncology Nursing Protocol Education Policy 
*** Remember to check the ALERT PAGE*** 
              SPECIAL NURSING CONSIDERATIONS UNIQUE TO THIS PROTOCOL Study 
Design 
  Pembrolizumab  is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa 
isotype designed to directly block the interact ion between PD-1 and its ligands, PD-L1 and PD-L2.  
 The Study Design is in Section 2 
 The Study Rationale is in Section 4.3 
 A cycle is defined as 21 days– Section 7.1 Dose 
Calc.  Pembrolizumab  is dosed in mg and is a fixed dose (Table 2) 
 Study Drug  
Administration Agent Administration  Guidelines are found in Section 7 
 Pembrolizumab  is given intravenously every 3 weeks(Section 7.1.1 
 Pembrolizumab  is administered over 30 minutes. A window of -5 minutes to +10 minutes is acceptable (Section 
7.1.1) 
 Criteria to treat in section 8.1 
 Dose  
Mods & 
Toxicity Dose Modifications/Dosing Delay for Toxicity  are outlined in Section 8.1 
 This protocol uses NCI CTCAE cr iteria, version 4.0 (Section 9.8.2) 
 Con 
Meds Concomitant Therapy  Guidelines are in Section 7.3 
 Permitted concomitant medications are in section 7.3.1 
 Prohibited concomitant medications are in section 7.3.2 Required  
Data  Study Calendar and Assessment Required data  are outlined in Section 12 
 The study calendar is in Section 12 
 Vital signs:  The time points are in Section 12.  
o Specific vital sign guidelines for infusion reactions are listed in Section 8, Table 4 
 PKs: The time points are in Section 12 
 Biomarkers : The time points are in Section 12 Charting Tips All study drugs require documentat ion of exact administration time. 
Please be sure to DOCUMENT study medication actual  UP/DOWN times in medical record (e.g. LMR, eMAR, 
nursing notes). Edit eMAR as needed to match the exact time given . 
 If there is a discrepancy in the infusion time, delay in  administration, or the infusion takes longer than is 
permitted by the guidelines of the protocol, please document the reason for the discrepancy in the medical 
record.   
Please be sure to also DOCUMENT any required observation periods, any additional vital signs, routes of 
administration, injection sites, and exact time of PK collections. 
 
 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
 
 
 
 
 
 
  
PHARMACY MANUAL 
 
PEMBROLIZUMAB (MK-3475) 
KEYNOTE 289 
 
 
  Merck Sharp & Dohme Corp., NJ, USA  
 
 

Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 1
 
 
SUMMARY OF REVISIONS 
 
The following are a list of revisions to the Pharmacy Manual for pembrolizumab 
(MK-3475): 
 
 
Revision Date Revisions to Document New Version #: 
10-Dec-14  Global change: updated MK-3475 to pembrolizuma
b2.0 
 10-Dec-14  Global change: Inserted header Pembrolizumab (MK-3475) Pharmacy Manual for Investigational Studies 2.0 
10-Dec-14 Expanded table of contents 2.0 
10-Dec-14 Remove d trailin g zeros after decimal points 2.0 
10-Dec-14 Section 2:  
Revised footnote 1 in trial treatment table2.0 
10-Dec-14  Section 3.1: Removed text, “The pH is maintained usin
g a 10 mM histidine buffe r”2.0 
 10-Dec-14  Section 3.2:  Added text to emphasize normal saline as preferred diluent   Insert cautionary statement regarding drug transport and delivery  
 
Inserted text that any deviation from the guidance listed in this manual, must be discussed with sponso
r 2.0 
10-Dec-14  Section 3.3: Clarified weight based dosing calculation for changes in weight (10% rule)   Removed calculation for 200 m
g fixed dosin g2.0 
10-Dec-14  Section 3.4:  Clarified preferred method of dose preparation as 
volumetric reconstitution  Clarified reconstitution technique.2.0 
10-Dec-14  Section 3.6: 2.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 2
 
 
Inserted text stating infusion rates may differ for 
infusion reactions  Inserted text that entire bag needs to be dosed during infusion  Removed text regarding excess volume preparation   Added text to document volume administered per DEG instructions
10-Dec-14  Section 4.2  Added text to emphasize normal saline as preferred diluent  Insert cautionary statement regarding drug transport and delivery   Inserted text that any deviation from the guidance listed in this manual, must be discussed with sponso
r 2.0 
10-Dec-14  Section 4.3: Clarified weight based dosing calculation for changes in weight (10% rule)   
Removed calculation for 200 m
g fixed dosin g2.0 
10-Dec-14 
 Section 4.4: Clarified preferred method of dose preparation as 
volumetric method2.0 
10-Dec-14  Section 4.5: Inserted text stating infusion rates may differ for infusion reactions  Inserted text that entire bag needs to be dosed during infusion  Removed text regarding excess volume preparation  Added text to document volume administered per DEG instructions2.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 3
 
 
21-Oct-15 Section 2: 
 
Text added to footnote 2 for sourcing and recording of lot number, manufacturer, and expiry 
date.   3.0 
21-Oct-15 Section 3.2: 
 
Added guidance for collection of the following 
diluent information (manufacturer, lot, and expiry).  Removed the following text, “ unless instructed by the sponsor in writing” in the following sentence :  Pembrolizumab (MK-3475) SHOULD NOT BE MIXED WITH OTHER DILUENTS unless instructed by the SPONSOR in writing. 
 
Added diluted drug product in the following sentence:  
 
Sites should follow their SOPs for drug transport and delivery, with all po ssible effort to minimize 
agitation of the reconstituted and diluted drug 
product between the phar macy and the clinic 
 3.0 
21-Oct-15 Section 3.3: 
 
Clarified re-calculation of weight based dosing 
guidance.   3.0 
21-Oct-15 Section 3.5  
 Additional text added fo r concentration range 
requirements.   3.0 
21-Oct-15 Section 3.7: 
 Removed chemotherapeutic waste designation for solution remainin
g in vials that must be discarded. 3.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 4
 
 
 
21-Oct-15 Section 4.1:  
 
Text added about cap color.   3.0 
  21-Oct-15    Section 4.2:   Added guidance for collection of the following diluent information (manufacturer, lot, and expiry).    3.0 
21-Oct-15 Section 4.3: 
 Clarified re-calculation of weight based dosing 
guidance.   3.0 
21-Oct-15 Section 4.4: 
 Additional text added fo r concentration range 
requirements.   3.0 
21-Oct-15 Section 4.5: 
 Added the following text regarding infusion set materials:  *Contact Sponsor for materials not listed above   3.0 
21-Oct-15 Section 4.6: 
 Added text for discardin
g used vials. 3.0 
28-Feb-17 Section 2.0: 
 Updated footnote in trial treatment table to include SmPC and guidance rega rding locally sourced 
dru
g. 4.0 
28-Feb-17 Section 3.1  4.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 5
 
 
 
Added text statin g formulation is latex free
28-Feb-17 Section 3.2 
 Added rounding guidance.   Added guidance on temperature excursions.  
Clarified 4 hour room te mperature time limitation. 
 
Updated lan
guage around particulates.4.0 
28-Feb-17 Section 3.3 
 Updated units from lb to kg to align with weight 
based dosin g examples. 4.0 
28-Feb-17 Section 3.4  
 Clarified use of biosafety cabinets.  Updated gravimetric dosing guidance.   Added statement for use of spikes.   Updated text for potential for foaming.   4.0 
28-Feb-17 Section 3.5  
 Deleted duplicate text rega rding use of biosafety 
cabinets.   Updated text regarding fo rmation of particulates. 
 4.0 
28-Feb-17 Section 3.6 
 Added guidance for preparation of placebo.   4.0 
28-Feb-17 Section 3.7 
 Added instructional text that states 250mL volume is onl
y applicable to wei ght based studies.4.0  
28-Feb-17 Section 3.8 4.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 6
 
 
 
Clarified instructions for return of u n-usedvials. 
28-Feb-17 Section 4.1  
 Added text stating formulation is latex free.  Updated cap color for liquid formulation.  
Added text re
gardin g overfill volume. 4.0 
28-Feb-17 Section 4.2 
 
Added rounding guidance.   Added guidance on temperature excursions.  Clarified 4 hour room te mperature time limitation. 
 Updated lan
guage around particulates.4.0 
28-Feb-17 Section 4.3 
 Updated units from lb to kg to align with weight 
based dosin g examples.4.0 
28-Feb-17 Section 4.4  
 Clarified use of biosafety cabinets.  Updated gravimetric dosing guidance.   Added statement for use of spikes.   Updated text for potential for foaming.   4.0 
28-Feb-17 Section 4.5  
 Added guidance for preparation of placebo.  4.0 
28-Feb-17 Section 4.6 
 Added instructional text that states 250mL volume is only applicable to weight based studies. 
 4.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 7
 
 
Additional text added regarding formation of 
foam.  
28-Feb-17 Section 4.7 
 Clarified instructions for return of u
n-usedvials.4.0  
21-Mar-2018 Section 1.0: 
 Added unblinded clinical sc ientist to contact list 
Updated CDS title to CS Updated IVRS to IRT throughout document  5.0 
  21-Mar-2018 Section 3.2  Added text for temperature excursions that temperature data needs to be included in clinical 
complaint.   Clarified for blinded studies that uCRA should be contacted for temperature excursions.   Updated the room temperature allowance from 4 hours to 6 hours and clarified fridge time allowance.   Clarified the start of room temperature time.  5.0 
21-Mar-2018  Section 3.6  Revised flushing statement.  Section 3.7  Updated drug destruction instructions.  5.0 
  21-Mar-2018 Section 4.2  Added text for temperature excursions that temperature data needs to be included in clinical 
complaint.   5.0 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 8
 
 
Clarified for blinded studies that uCRA should be 
contacted for temperature excursions.   Updated the room temperature allowance from 4 hours to 6 hours and clarified fridge time allowance.  Clarified the start of room temperature time.  
21-Mar-2018 Section 4.4 
 Updated room temperature time allowance to 6 hours and clarified cumulative storage time.   5.0 
21-Mar 2018 Section 4.5: 
 Revised flushing statement.  Section 4.6:  Updated drug destruction instructions.  5.0 
 
 
 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 9
 
 
TABLE OF CONTENTS 
Contents 
1. Contact List ............................................................................................................... .... 10 
2. Trial Treatment ............................................................................................................ . 11 
3.  Drug Preparation – Pembrolizumab (MK-3475) Solution for Infusion ................. 12  
3.1 DRUG PRODUCT ............................................................................................. 12  
3.2 STABILITY AND HANDLING OF DRUG PRODUCT ................................. 12  
3.3 DOSE CALCULATION .................................................................................... 14  
4.4 PREPARATION OF INFUSION SOLUTION.................................................. 14  
3.5 ADMINISTRATION ......................................................................................... 17  
3.6 RETURN AND DISCARDING OF PEMBROLIZUMAB (MK-3475) VIALS
 19  
 
 
  
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 10
 
 
 
1. Contact List 
 
Merck Sharp & Dohme Corp., NJ, USA  (Pharmacy Manual questions only)  
For questions regarding the details outlined within this Pharmacy Manual, please contact 
your clinical scientist (CS)   
Waheeda Sirah , Associate Prin. Scientist 
Phone:  1-732-594-2230  
E-mail:  waheeda_sirah@merck.com  
 
 
	
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018   
  
 11
 
 
2. Trial Treatment  
 
Trial Treatment Table 
 
Drug Dose/PotencyDose 
FrequencyRoute of 
Administration  Regimen/ 
Treatment 
Period Use
pembrolizumab 
(MK-3475) 1 2 or 10 mg/kg Q3W IV infusion Day 1 of each 
cycle1 Experimental 
1 Refer to protocol for specific study drug administration sequence for combination studies of pembrolizumab (MK-3475) 
and chemo/immunotherapy  
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 12
 
 
 
3.  Drug Preparation – Pembrolizumab  (MK-3475) Solution for 
Infusion 
3.1 DRUG PRODUCT  
 Pembrolizumab (MK-3475) Solution for Infusion, 100 mg/ 4 mL vial 
 
 Pembrolizumab (MK-3475) Solution for Infu sion is a sterile, non-pyrogenic aqueous 
solution supplied in single-use Type I glass vial containi ng 100 mg/4 mL of 
pembrolizumab (MK-3475). The product is pres ervative-free, latex free solution which 
is essentially free of extraneous particulates. 
 
 Cap color of MK-3475 (Pembrolizumab) 100 mg vials: 
 
 Both red, salmon, and blue color cap s may be used. Though the cap color 
may be different, the product inside the vial is the same MK-3475 drug 
product. 
 
 Pembrolizumab (MK-3475) Solution for Infusion  vials are filled to a target of 4.25mL 
(106.25mg) to ensure recovery of 4.0mL (100mg). 
 
 3.2 STABILITY AND HANDLING OF DRUG PRODUCT  
 Pembrolizumab (MK-3475) Solution for Infusion, 100 mg/ 4 mL vial :  
pembrolizumab (MK-3475) Solution for Infusion vials should be st ored at refrigerated 
conditions 2 – 8 °C (36 - 46 °F) and protected from light. 
 
 To determine whether to report a temperature excursion, the temperature values should 
be rounded to whole numbers. 
      
 Rounding: 
 
o Decimal values from 0.1 to 0.4 round down to the nearest whole number  
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 13
 
 
(e.g., 8.3 = 8) 
o Decimal values from 0.5 to 0.9 round  up to the nearest whole number  
(e.g., 8.7 = 9) 
 Then compare the rounded values to the re quired temperature range to determine if 
there's an excursion. 
 All temperature excursions, however small, mu st be reported by the site to the Clinical 
Complaint Intake mailbox (clinical.compla ints.intake@merck.com) for investigation 
within 1 business day using th e Clinical Supply Complaint & GCP Inquiry Form (excel 
version) and attached temperature data.  All C linical Supply stock that is subject to an 
investigation must be placed in quarantin e and remain unavailable to dispense to 
patients until disposition has been determined. 
 Please note temperature excursions after drug product is prepared are out of scope of 
the clinical complaint process. Please contact HQ clinical study team for further 
guidance.  
Note : vials should be stored in the original box to ensu re the drug product is protected    
from light.  
 Pembrolizumab (MK-3475)  infusion solutions should be prepared in 0.9% Sodium 
Chloride Injection, USP  (normal saline) or regional equivalent or 5% Dextrose 
Injection, USP (5% dextrose) or regional eq uivalent and the final concentration of 
pembrolizumab (MK-3475)  in the infusion solutions should  be between 1 mg/mL and 10 
mg/mL.  
 
 Please note, the preferred diluent is 0.9% S odium Chloride and 5% dextrose is only 
permissible if normal saline is not available. 
 
 Local guidelines should be followed for co llection of diluent information such as 
manufacturer, lot and expiry. When the diluent is provided by Merck, the drug 
accountability log should be used for collection of diluent information. 
 
 Pembrolizumab (MK-3475)  SHOULD NOT  BE MIXED WITH OTHER DILUENTS.  
 
 Pembrolizumab (MK-3475) solutions may be  stored at room temperature for a 
cumulative time of up to 6 hours. The 6 hour c ountdown begins when the vial is pierced, 
and includes room temperature storage of ad mixture solutions in the IV bags and the 
duration of infusion. (Please note this 6 hour tim eframe is to provide a microbial control 
strategy. The microbial clock only starts when the product stopper is pierced and not 
when the vial is removed from the refrigerator.) 
 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 14
 
 
 In addition, IV bags may be st ored under refrigerati on at 2 °C to 8 °C (36 °F to 46 °F), 
total cumulative storage time at room temper ature and refrigeration should not exceed 24 
hours.  
 
 If refrigerated, allow the IV bags to come to room temperature prior to use.   
 
 Parenteral drug products shou ld be inspected visually for particulate matter and 
discoloration prior to administration. Discard the drug produc t vial if visible particles are 
observed. 
 
    Sites should follow their SOPs for drug tr ansport and delivery, w ith all possible effort 
to minimize agitation of the drug produc t between the pharmacy and the clinic 
 
 DO NOT USE PEMBROLIZUMAB (MK-3475) IF DISCOLORATION IS 
OBSERVED . 
 
 DO NOT SHAKE OR FREEZE THE VIAL(S). 
 
 DO NOT ADMINISTER THE PRODUCT AS AN INTRAVENOUS (IV) PUSH OR 
BOLUS. 
 
 DO NOT COMBINE, DILUTE OR ADMIN ISTER IT AS AN INFUSION WITH 
OTHER MEDICINAL PRODUCTS. 
 
 Any departure from the guidance listed in  this manual, must be discussed with 
sponsor 
  
3.3 DOSE CALCULATION 
 
Follow directions applicable to th e dose level (mg/kg) of the study. 
 200 mg Fixed Dose 
 
  2 vials (100 mg/4 mL) 
  8 mL total  
   4.4 PREPARATION OF INFUSION SOLUTION 
 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 15
 
 
 
 Aseptic technique must be strictly obse rved throughout the prep aration procedure  
 
    Use of a biosafety cabinet is preferred since no anti-microbial preservative is present 
in the product; however, it is not mandatory unless specified by site  standard operating 
procedure. 
 
 Equilibrate required number of pembrolizu mab MK-3475 vials to room temperature 
 
 The preferred method of dose prepar ation is the volumetric method 
 
 Sponsor recommends reconstitution and ad ministration of pembrolizumab (MK-3475) 
that follows the parameters in this manual, however if use of gravimetric preparation is 
mandatory due to local site procedures, the following requirements must be satisfied and 
documented: 
 Draw the required volume up to 4.0 mL (100 mg) of pembrolizumab from each 
vial 
 Limit the number of punctures  of each vial to one 
 
 For gravimetric preparation method using dens ity of pembrolizumab solution, a value of 
1.03 g/mL should be used 
 
 Merck does not support methods of preparat ion of non-Merck agents beyond what is 
stated in the product literatu re.  Sites should reference th e SmPCs or packaging inserts 
for preparation instructions 
 
 If the site procedures require use of spikes  or other closed system transfer devices 
(CSTDs), please contact sponsor for approval 
 
 Choose a suitable infusion bag size so that the following conditions are met: 
 Concentration of pembrolizumab MK-3475  is between 1 mg/mL and 10 
mg/mL 
 The infusion volume to bag capacity ratio should not be less than 0.3.  In other words, the bag must be filled to at least 30% of its capacity.   
 
 Choose a suitable infusion bag material. The bag may be empty or it may contain normal 
saline The following infusion bag materials are compatible with pembrolizumab (MK-
3475):  
 
 PVC plasticized with DEHP 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 16
 
 
 Non-PVC (polyolefin) 
 EVA 
 PE lined polyolefin 
      *Contact Sponsor for materials not listed above 
 
 Calculate the volume of pembrolizumab (MK-3475) and normal saline required to 
prepare the infusion (admixture) bag 
 
Volume of pembrolizumab (MK-3475)  (mL) = required dose amount (mg) / 25 (mg/mL) 
 
Volume of normal saline = total infusion volume – volume of pembrolizumab (MK-3475) 
from above  
 If a bag pre-filled with normal saline is being used, remove the excess volume of normal saline using a sterile syringe (Polypropylene, latex-free) attached to a suitable needle. 
Keep in consideration the excess bag fill vol ume as well as the volume of pembrolizumab 
(MK-3475)  to be added to the bag to prepare the infusion solution. This helps ensure that 
the concentration in the bag can be accurately calculated and falls within the acceptable 
range of 1 mg/mL to 10 mg/mL. If the site would like to proceed without removing excess 
saline they must ensure that  the concentration of MK- 3475 would still fall within 
acceptable range. 
 
 If an empty bag is being us ed, withdraw the necessary vo lume of normal saline from 
another appropriate bag and in ject into the empty bag. Keep in consideration the volume 
of pembrolizumab (MK-3475)  to be added to the bag to prepare the infusion solution. 
 
 Withdraw the required volume of pembrolizumab (MK-3475) from the vial(s) (up to 4 
mL from each vial) using a ster ile syringe attached to a suitable needle. The vial(s) may 
need to be inverted to remove solution. 
 
Volume of pembrolizumab (MK-3475)  (mL) = required dose amount (mg) / 25 (mg/mL) 
 
Note:  If it is necessary to use seve ral vials, it is advisable to  withdraw from several vials 
into a suitable size single use syringe using a new needle for each vial.  
 
 Add the required pembrolizumab (MK-3475)  into the infusion IV bag containing normal 
saline and gently invert the bag 10-15 times to mix the solution. 
 
 Pembrolizumab (MK-3475)  solutions may be stored at room temperature for a 
cumulative time of up to 6 hours. This includes room temperature storage of admixture solutions in the IV bags a nd the duration of infusion.  
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 17
 
 
 
 In addition, IV bags may be st ored under refrigerati on at 2 °C to 8 °C (36 °F to 46 °F), 
total cumulative storage time at room temper ature and refrigeration should not exceed 24 
hours.  
 
 If refrigerated, allow the IV bags to come to room temperature prior to use.   
 
 If the infusion bag is excessively handled or shaken, particulates may form. If this occurs 
discard the bag and create a new bag taking care not to shak e. Please contact your HQ 
clinical study team if particulates are noticed for further instructions.  Be prepared to 
provide the following information: 
 IV bag manufacture, lot and expiry 
 Target volume of admixt ure solution in the IV bag (e.g. 100 mL, 200 mL etc.) 
 Amount of drug product (mL or mg) added to the bag 
 Drug product lot 
 Brief description of the nature of visible particles (color, shape, size, numbers 
etc.). 
  
 DO NOT FREEZE THE PEMBRO LIZUMAB (MK-3475) INFUSION 
SOLUTION. 
 
 Discard any unused portion left in the vial  as the product contains no preservative 
 
3.5 ADMINISTRATION 
 
 Pembrolizumab (MK-3475)  infusions should be administered in 30 minutes, with a 
window of -5 and +10 minutes, using an infusi on pump. A central cath eter is not required 
for infusion; however, if a subject has a central venous catheter in place, it is 
recommended that it be used for the infusion.  
 
 The following infusion set materials are co mpatible with (pembrolizumab) MK-3475: 
 
o PVC Infusion set that is plasticized using DEHP 
o PVC and tri-(2-ethylhexyl) trimellitate (TOTM) infusion set 
o Polyethylene lined PVC infusion set 
o PVC Infusion set that is plasticized using Di-2-ethylhexyl Terephthalate 
(DEHT) 
o Polyurethane set 
 
*Contact Sponsor for materials not listed above 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 18
 
 
 
 A sterile, non-pyrogenic, low-protein bind ing 0.2 to 5 µm in-linefilter made of 
polyethersulfone (PES) must be used during administration to remove any adventitious 
particles.  If the infu sion set does not contain 0.2 to 5 µm in-line filt er, it is recommended 
to use 0.2 to 5 µm add-on filter which may cont ain an extension line (Note: the materials 
of the extension line and filter should be as mentioned above). 
 
 Attach the infusion line to the pump and prime the line, either with normal saline (at least 
25 mL) or with infusion solution as per local SOP, before starting the infusion. 
 
 Infuse pembrolizumab (MK-3475) over appr oximately 30 minutes, with a window of  
        -5 and +10 minutes, through a peripheral line or i ndwelling catheter.  
 
 Ensure the entire contents of the bag are dosed  and all remaining drug solution in the line 
is administered through saline flushing.  
 
 Document volume administered according to data entry guidelines. 
 
 In case of infusion reactions, infusion rate may differ; refer to protocol for specific 
instructions.   
 
 Whenever possible, the lowest infusion rate should be used that will allow completion of 
the infusion within the 30 minutes.  
 
 Maximum rate of infusion should not exceed 6.7 mL/min. through a peripheral line or indwelling catheter.  
 However, when it is necessary to infuse a la rger volume (i.e. 250 mL), the flow rate may 
go as high as 10 mL/min (maximum) in order to keep the infusion within the window as 
defined above.  
 
 
 DO NOT CO-ADMINISTER OTHE R DRUGS THROUGH THE SAME 
INFUSION LINE. 
 
 UNUSED INFUSION SOLUTION FOR INJECTION SHOULD NOT BE USED 
FOR ANOTHER INFUSION OF THE SAME SUBJECT OR DIFFERENT 
SUBJECT. 
 
Pembrolizumab (MK-3475) Pharmacy Manual for Investig ational Studies 
Template Version 5.0  
21-Mar- 2018 Study Version 3.0 10-MAY-2018    
 19
 
 
 Caution: Do not shake the vials/bags otherw ise this may result in formation of foam. 
If foam is noticed in either vial or bag, th e drug product will need to be discarded. 
A new preparation should be made, taking care not to shake or agitate the product. 
 
3.6 RETURN AND DISCARDING OF PEMB ROLIZUMAB (MK-3475) VIALS 
 
Unused pembrolizumab (MK-3475) Solution for In fusion vial(s) shall be returned to the 
designated facility for destruction.  
o For US clinical sites, return to the central depot th at shipped supplies to the 
site:  
 Fisher Clinical Services, Return and Destruction Center, 700B Nestle 
Way, Breinigsville, PA 18031 
 Merck & Co., Inc. 770 Sumneytown Pike B-78A West Point, PA 19486 
 
o For ex-US clinical sites, consult with  local Merck subsidiary for facility 
address. 
 
     Solution remaining in a used vial should be discarded according to your local 
procedures. 
 
     Any information on the label identifyi ng the subject should be redacted prior to 
returning the study medication. 
       
 
    
 
 